Cover Page
Cover Page - shares | 9 Months Ended | |
Sep. 30, 2023 | Oct. 16, 2023 | |
Cover [Abstract] | ||
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Sep. 30, 2023 | |
Document Transition Report | false | |
Entity File Number | 1-8036 | |
Entity Registrant Name | WEST PHARMACEUTICAL SERVICES, INC. | |
Entity Incorporation, State or Country Code | PA | |
Entity Tax Identification Number | 23-1210010 | |
Entity Address, Address Line One | 530 Herman O. West Drive | |
Entity Address, City or Town | Exton | |
Entity Address, State or Province | PA | |
Entity Address, Postal Zip Code | 19341-1147 | |
City Area Code | 610 | |
Local Phone Number | 594-2900 | |
Title of each class | Common Stock, par value $0.25 per share | |
Trading Symbol | WST | |
Security Exchange Name | NYSE | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Large Accelerated Filer | |
Entity Small Business | false | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 73,989,670 | |
Entity Central Index Key | 0000105770 | |
Current Fiscal Year End Date | --12-31 | |
Document Fiscal Year Focus | 2023 | |
Document Fiscal Period Focus | Q3 | |
Amendment Flag | false |
CONDENSED CONSOLIDATED STATEMEN
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) - USD ($) shares in Millions, $ in Millions | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Income Statement [Abstract] | ||||
Net sales | $ 747.4 | $ 686.9 | $ 2,217.8 | $ 2,178.2 |
Cost of goods and services sold | 459.1 | 418.9 | 1,366.8 | 1,304.1 |
Gross profit | 288.3 | 268 | 851 | 874.1 |
Research and development | 16.4 | 13.6 | 50 | 42.6 |
Selling, general and administrative expenses | 89 | 66.3 | 263.4 | 231.2 |
Other expense (income) (Note 15) | 5.6 | 1.9 | 22.5 | (4) |
Operating profit | 177.3 | 186.2 | 515.1 | 604.3 |
Interest expense | 2.9 | 2.2 | 7.8 | 6.2 |
Interest income | (8.8) | (1.5) | (18.6) | (2.2) |
Other nonoperating (income) expense | (3.8) | 49.3 | (3.9) | 49.1 |
Income before income taxes and equity in net income of affiliated companies | 187 | 136.2 | 529.8 | 551.2 |
Income tax expense | 29.4 | 20.4 | 87.8 | 85.8 |
Equity in net income of affiliated companies | (3.7) | (4.8) | (14.4) | (17.5) |
Net income | $ 161.3 | $ 120.6 | $ 456.4 | $ 482.9 |
Net income per share: | ||||
Basic (in dollars per share) | $ 2.17 | $ 1.62 | $ 6.13 | $ 6.49 |
Diluted (in dollars per share) | $ 2.14 | $ 1.59 | $ 6.05 | $ 6.36 |
Weighted average shares outstanding: | ||||
Basic (in shares) | 74.3 | 74.4 | 74.4 | 74.4 |
Diluted (in shares) | 75.3 | 75.7 | 75.5 | 75.9 |
CONDENSED CONSOLIDATED STATEM_2
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Statement of Comprehensive Income [Abstract] | ||||
Net income | $ 161.3 | $ 120.6 | $ 456.4 | $ 482.9 |
Other comprehensive (loss) income, net of tax: | ||||
Foreign currency translation adjustments, net of tax of $0.4, $1.1, $1.9 and $3.8, respectively | (40.9) | (76) | (36.9) | (162.5) |
Defined benefit pension and other postretirement plan adjustments, net of tax of $0.0, $14.6, $(0.5), and $15.5, respectively | 0.2 | 13.6 | (1.2) | 16.4 |
Net loss on equity affiliate accumulated other comprehensive income, net of tax of $0.0, $0.0, $0.0 and $0.0, respectively | 0 | (0.1) | (0.1) | (0.2) |
Net gain (loss) on derivatives, net of tax of $0.8, $0.0, $(0.3) and $(0.8), respectively | 1.2 | (0.1) | (1.8) | (2.6) |
Other comprehensive (loss) income, net of tax | (39.5) | (62.6) | (40) | (148.9) |
Comprehensive income | $ 121.8 | $ 58 | $ 416.4 | $ 334 |
CONDENSED CONSOLIDATED STATEM_3
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) (Parenthetical) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Statement of Comprehensive Income [Abstract] | ||||
Foreign currency translation adjustments, tax | $ 0.4 | $ 1.1 | $ 1.9 | $ 3.8 |
Defined benefit pension and other postretirement plan adjustments, tax | 0 | 14.6 | (0.5) | 15.5 |
Net loss on equity affiliate accumulated other comprehensive income, tax | 0 | 0 | 0 | 0 |
Net gain (loss) on derivatives, tax | $ 0.8 | $ 0 | $ (0.3) | $ (0.8) |
CONDENSED CONSOLIDATED BALANCE
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($) $ in Millions | Sep. 30, 2023 | Dec. 31, 2022 |
Current assets: | ||
Cash and cash equivalents | $ 898.6 | $ 894.3 |
Accounts receivable, net | 519.1 | 507.4 |
Inventories | 431.8 | 414.8 |
Other current assets | 122.8 | 103 |
Total current assets | 1,972.3 | 1,919.5 |
Property, plant and equipment | 2,607.1 | 2,386.6 |
Less: accumulated depreciation and amortization | 1,295.5 | 1,228.3 |
Property, plant and equipment, net | 1,311.6 | 1,158.3 |
Operating lease right-of-use assets | 96.8 | 104.4 |
Investments in affiliated companies | 195.4 | 204.9 |
Goodwill | 106.8 | 107.3 |
Intangible assets, net | 15.7 | 18.4 |
Deferred income taxes | 17.3 | 65.6 |
Other noncurrent assets | 38.8 | 38.4 |
Total Assets | 3,754.7 | 3,616.8 |
Current liabilities: | ||
Notes payable and other current debt | 55.2 | 2.2 |
Accounts payable | 219.8 | 215.4 |
Accrued salaries, wages and benefits | 90.5 | 76.8 |
Income taxes payable | 15 | 24.8 |
Operating lease liabilities | 16.5 | 16 |
Other current liabilities | 136.5 | 183.8 |
Total current liabilities | 533.5 | 519 |
Long-term debt | 152.1 | 206.7 |
Deferred income taxes | 16.5 | 14.3 |
Pension and other postretirement benefits | 28.4 | 28.2 |
Operating lease liabilities | 83 | 93 |
Deferred compensation benefits | 17.9 | 19.1 |
Other long-term liabilities | 55.1 | 51.6 |
Total Liabilities | 886.5 | 931.9 |
Commitments and contingencies (Note 17) | ||
Equity: | ||
Preferred stock, 3.0 million shares authorized; 0 shares issued and outstanding | 0 | 0 |
Common stock, par value $0.25 per share; 200.0 million shares authorized; shares issued: 75.3 million and 75.3 million, respectively; shares outstanding: 74.0 million and 74.1 million, respectively | 18.8 | 18.8 |
Capital in excess of par value | 122.6 | 232.2 |
Retained earnings | 3,415.9 | 2,987.8 |
Accumulated other comprehensive loss | (223) | (183) |
Treasury stock, at cost (1.3 million and 1.2 million shares, respectively) | (466.1) | (370.9) |
Total Equity | 2,868.2 | 2,684.9 |
Total Liabilities and Equity | $ 3,754.7 | $ 3,616.8 |
CONDENSED CONSOLIDATED BALANC_2
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) - $ / shares | Sep. 30, 2023 | Dec. 31, 2022 |
Statement of Financial Position [Abstract] | ||
Preferred stock, shares authorized (in shares) | 3,000,000 | 3,000,000 |
Preferred stock, shares issued (in shares) | 0 | 0 |
Preferred stock, shares outstanding (in shares) | 0 | 0 |
Common stock, par value (in dollars per share) | $ 0.25 | $ 0.25 |
Common stock, shares authorized (in shares) | 200,000,000 | 200,000,000 |
Common stock, shares issued (in shares) | 75,300,000 | 75,300,000 |
Common stock, shares outstanding (in shares) | 74,000,000 | 74,100,000 |
Treasury stock, at cost (in shares) | 1,300,000 | 1,200,000 |
CONDENSED CONSOLIDATED STATEM_4
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Millions | 9 Months Ended | |
Sep. 30, 2023 | Sep. 30, 2022 | |
Cash flows from operating activities: | ||
Net income | $ 456.4 | $ 482.9 |
Adjustments to reconcile net income to net cash provided by operating activities: | ||
Depreciation | 99.1 | 86.8 |
Amortization | 2.3 | 2.7 |
Stock-based compensation | 21.9 | 17 |
Loss on disposal of plant | 11.6 | 0 |
Asset impairments | 6.9 | 1.6 |
Pension settlement charge | 0 | 50.8 |
Other non-cash items, net | (13.5) | (17.9) |
Changes in assets and liabilities | (47.3) | (130.7) |
Net cash provided by operating activities | 537.4 | 493.2 |
Cash flows from investing activities: | ||
Capital expenditures | (253.3) | (189.7) |
Other, net | (6.6) | (3.7) |
Net cash used in investing activities | (259.9) | (193.4) |
Cash flows from financing activities: | ||
Repayments of long-term debt | (1.7) | (43.7) |
Debt issuance costs | 0 | (1.3) |
Dividend payments | (42.2) | (40) |
Proceeds from stock-based compensation awards | 42.6 | 17.1 |
Employee stock purchase plan contributions | 5.3 | 6.1 |
Shares purchased under share repurchase programs | (261.3) | (202.9) |
Shares repurchased for employee tax withholdings | (12.8) | (19.4) |
Net cash used in financing activities | (270.1) | (284.1) |
Effect of exchange rates on cash | (3.1) | (49.3) |
Net increase (decrease) in cash and cash equivalents | 4.3 | (33.6) |
Cash, including cash equivalents at beginning of period | 894.3 | 762.6 |
Cash, including cash equivalents at end of period | $ 898.6 | $ 729 |
Basis of Presentation and Summa
Basis of Presentation and Summary of Significant Accounting Policies | 9 Months Ended |
Sep. 30, 2023 | |
Accounting Policies [Abstract] | |
Basis of Presentation and Summary of Significant Accounting Policies | Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation : The condensed consolidated financial statements included in this report are unaudited and have been prepared in accordance with United States (“U.S.”) generally accepted accounting principles (“U.S. GAAP”) for interim financial reporting and U.S. Securities and Exchange Commission (“SEC”) regulations. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, these financial statements include all adjustments, which are of a normal recurring nature, necessary for a fair statement of the financial position, results of operations, cash flows and the change in equity for the periods presented. The condensed consolidated financial statements for the three and nine months ended September 30, 2023, should be read in conjunction with the consolidated financial statements and notes thereto of West Pharmaceutical Services, Inc. and its majority-owned subsidiaries (which may be referred to as “West”, the “Company”, “we”, “us” or “our”) appearing in our Annual Report on Form 10-K for the year ended December 31, 2022 (the “ 2022 Annual Report ”). The results of operations for any interim period are not necessarily indicative of results for the full year. |
New Accounting Standards
New Accounting Standards | 9 Months Ended |
Sep. 30, 2023 | |
Accounting Standards Update and Change in Accounting Principle [Abstract] | |
New Accounting Standards | New Accounting Standards Recently Adopted Standards In September 2022, the Financial Accounting Standards Board ("FASB") issued guidance that seeks to enhance transparency around entities' use of supplier finance programs. The amendment requires the buyer in a supplier finance program to disclose information about the key terms of the program, outstanding confirmed amounts as of the end of the period, a rollforward of such amounts during each annual period, and a description of where in the financial statements outstanding amounts are presented. This guidance is effective for fiscal years beginning after December 15, 2022. We adopted this guidance as of January 1, 2023, on a prospective basis. The adoption did not have a material impact on our financial statements, as supplier finance programs are not material to the Company as of September 30, 2023. |
Revenue
Revenue | 9 Months Ended |
Sep. 30, 2023 | |
Revenue from Contract with Customer [Abstract] | |
Revenue | Revenue Our revenue results from the sale of goods or services and reflects the consideration to which we expect to be entitled in exchange for those goods or services. We record revenue based on a five-step model, in accordance with Accounting Standards Codification (“ASC”) 606. Following the identification of a contract with a customer, we identify the performance obligations (goods or services) in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract, and recognize the revenue when (or as) we satisfy the performance obligations by transferring the promised goods or services to our customers. A good or service is transferred when (or as) the customer obtains control of that good or service. The following table presents the approximate percentage of our net sales by market group: Three Months Ended Nine Months Ended 2023 2022 2023 2022 Biologics 40 % 41 % 37 % 42 % Generics 19 % 18 % 20 % 18 % Pharma 22 % 24 % 24 % 24 % Contract-Manufactured Products 19 % 17 % 19 % 16 % 100 % 100 % 100 % 100 % The following table presents the approximate percentage of our net sales by product category: Three Months Ended Nine Months Ended 2023 2022 2023 2022 High-Value Product Components 50 % 54 % 50 % 56 % High-Value Product Delivery Devices 11 % 6 % 10 % 5 % Standard Packaging 20 % 23 % 21 % 23 % Contract-Manufactured Products 19 % 17 % 19 % 16 % 100 % 100 % 100 % 100 % Due to the Company's reassessment of product categories, beginning in the second quarter of 2023, certain product types have been moved from High-Value Product Components to High-Value Product Delivery Devices. No adjustments were made to the product categorization prior to the second quarter of 2023. The following table presents the approximate percentage of our net sales by geographic location: Three Months Ended Nine Months Ended 2023 2022 2023 2022 Americas 46 % 53 % 45 % 48 % Europe, Middle East, Africa 46 % 38 % 46 % 43 % Asia Pacific 8 % 9 % 9 % 9 % 100 % 100 % 100 % 100 % Contract Assets and Liabilities The following table summarizes our contract assets and liabilities, excluding amounts included in accounts receivable, net: ($ in millions) Contract assets, December 31, 2022 $ 16.3 Contract assets, September 30, 2023 19.9 Change in contract assets - increase (decrease) $ 3.6 Deferred income, December 31, 2022 $ (68.2) Deferred income, September 30, 2023 (50.0) Change in deferred income - decrease (increase) $ 18.2 Contract assets are included within other current assets and deferred income is included within other current liabilities and other long-term liabilities. During the nine months ended September 30, 2023, $33.2 million of revenue was recognized that was included in deferred income at the beginning of the year. The majority of the performance obligations within our contracts are satisfied within one year or less. Performance obligations satisfied beyond one year include those relating to a nonrefundable customer payment of $20.0 million received in June 2013 in return for the exclusive use of the SmartDose ® technology platform within a specific therapeutic area. As of September 30, 2023, there was $2.4 million of deferred income related to this payment, of which $0.9 million was included in other current liabilities and $1.5 million was included in other long-term liabilities. The deferred income is being recognized as income on a straight-line basis over the remaining term of the agreement. The agreement does not include a future minimum purchase commitment from the customer. |
Net Income Per Share
Net Income Per Share | 9 Months Ended |
Sep. 30, 2023 | |
Earnings Per Share [Abstract] | |
Net Income Per Share | Net Income Per Share The following table reconciles the shares used in the calculation of basic net income per share to those used for diluted net income per share: Three Months Ended Nine Months Ended (in millions) 2023 2022 2023 2022 Net income $ 161.3 $ 120.6 $ 456.4 $ 482.9 Weighted average common shares outstanding 74.3 74.4 74.4 74.4 Dilutive effect of equity awards, based on the treasury stock method 1.0 1.3 1.1 1.5 Weighted average shares assuming dilution 75.3 75.7 75.5 75.9 During the three months ended September 30, 2023 and 2022, there were 0.0 million and 0.2 million shares, respectively, from stock-based compensation plans not included in the computation of diluted net income per share because their impact was antidilutive. There were 0.1 million and 0.1 million antidilutive shares outstanding during the nine months ended September 30, 2023 and 2022, respectively. In February 2023, the Board of Directors approved a share repurchase program under which we may repurchase up to $1.0 billion in shares of common stock. The share repurchase program does not have an expiration date under which we may repurchase common stock on the open market or in privately-negotiated transactions. The number of shares to be repurchased and the timing of such transactions will depend on a variety of factors, including market conditions. During the three months ended September 30, 2023, we purchased 77,329 shares of our common stock under the program at a cost of $27.8 million, or an average price of $360.25 per share. During the nine months ended September 30, 2023, we purchased 753,399 shares of our common stock under the program at a cost of $261.3 million, or an average price of $346.86 per share. In December 2021, we announced a share repurchase program for calendar-year 2022 authorizing the repurchase of up to 650,000 shares of our common stock from time to time on the open market or in privately-negotiated transactions. The number of shares to be repurchased and the timing of such transactions was dependent on a variety of factors, including market conditions. This share repurchase program was completed by December 31, 2022. During the three months ended September 30, 2022, we purchased 86,667 shares of our common stock under the calendar-year 2022 program at a cost of $27.2 million, or an average price of $313.22 per share. During the nine months ended September 30, 2022, we purchased 563,334 shares of our common stock under the calendar-year 2022 program at a cost of $202.9 million, or an average price of $360.03 per share. |
Inventories
Inventories | 9 Months Ended |
Sep. 30, 2023 | |
Inventory Disclosure [Abstract] | |
Inventories | Inventories Inventories are valued at the lower of cost (on a first-in, first-out basis) or net realizable value. Inventory balances were as follows: ($ in millions) September 30, December 31, Raw materials $ 180.2 $ 170.7 Work in process 93.8 79.0 Finished goods 157.8 165.1 $ 431.8 $ 414.8 |
Leases
Leases | 9 Months Ended |
Sep. 30, 2023 | |
Leases [Abstract] | |
Leases | Leases A lease exists when a contract conveys to the customer the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. The definition of a lease embodies two conditions: 1) there is an identified asset in the contract that is land or a depreciable asset (i.e., property, plant, and equipment); and 2) the customer has the right to control the use of the identified asset. Lease payments included in the measurement of the operating lease right-of-use assets and lease liabilities are comprised of fixed payments (including in-substance fixed payments), variable payments that depend on an index or rate, and the exercise price of a lessee option to purchase the underlying asset if the lessee is reasonably certain to exercise. The components of lease expense were as follows: Three Months Ended Nine Months Ended ($ in millions) 2023 2022 2023 2022 Operating lease cost $ 4.3 $ 3.7 $ 15.0 $ 10.4 Short-term lease cost 1.9 0.3 4.4 1.1 Variable lease cost 1.4 2.3 4.4 4.7 Total lease cost $ 7.6 $ 6.3 $ 23.8 $ 16.2 Supplemental cash flow information related to leases were as follows: Three Months Ended Nine Months Ended ($ in millions) 2023 2022 2023 2022 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 4.5 $ 3.7 $ 14.4 $ 10.0 Right-of-use assets obtained in exchange for new operating lease liabilities $ 3.1 $ 14.0 $ 6.6 $ 29.5 As of September 30, 2023 and December 31, 2022, the weighted average remaining lease term for operating leases was 10.1 years and 9.3 years, respectively. As of September 30, 2023 and December 31, 2022, the weighted average discount rate was 3.46% and 3.25%, respectively. Maturities of operating lease liabilities were as follows: ($ in millions) September 30, December 31, Year 2023 2022 2023 (remaining period as of) $ 4.8 $ 19.0 2024 19.1 18.1 2025 17.1 16.0 2026 14.1 13.4 2027 9.8 9.4 Thereafter 50.6 50.8 115.5 126.7 Less: imputed lease interest (16.0) (17.7) Total lease liabilities $ 99.5 $ 109.0 |
Affiliated Companies
Affiliated Companies | 9 Months Ended |
Sep. 30, 2023 | |
Equity Method Investments and Joint Ventures [Abstract] | |
Affiliated Companies | Affiliated Companies At September 30, 2023 and December 31, 2022, the aggregate carrying amount of our investment in affiliated companies that are accounted for under the equity method was $189.7 million and $197.0 million, respectively, and the aggregate carrying amount of our investment in affiliated companies that are not accounted for under the equity method was $5.7 million and $7.9 million, respectively. We record these investments, for which fair value was not readily determinable, at cost, less impairment, adjusted for subsequent observable price changes. We test these investments for impairment whenever circumstances indicate that the carrying value of the investments may not be recoverable. Our purchases from, and royalty payments made to, affiliates totaled $34.4 million and $118.5 million for the three and nine months ended September 30, 2023, respectively, as compared to $33.6 million and $131.2 million, respectively, for the same periods in 2022. As of September 30, 2023 and December 31, 2022, the payable balance due to affiliates was $20.6 million and $31.2 million, respectively. The majority of these transactions related to a distributorship agreement with Daikyo Seiko, Ltd. ("Daikyo") that allows us to purchase and re-sell Daikyo products. |
Debt
Debt | 9 Months Ended |
Sep. 30, 2023 | |
Debt Disclosure [Abstract] | |
Debt | Debt The following table summarizes our long-term debt obligations, net of unamortized debt issuance costs and current maturities. The interest rates shown in parentheses are as of September 30, 2023. ($ in millions) September 30, December 31, Term Loan, due December 31, 2024 (6.37%) $ 81.5 $ 83.2 Series B notes, due July 5, 2024 (3.82%) 53.0 53.0 Series C notes, due July 5, 2027 (4.02%) 73.0 73.0 207.5 209.2 Less: unamortized debt issuance costs 0.2 0.3 Total debt 207.3 208.9 Less: current portion of long-term debt 55.2 2.2 Long-term debt, net $ 152.1 $ 206.7 Credit Facility At September 30, 2023, the borrowing capacity available under our $500.0 million multi-currency revolving credit facility (the “Credit Facility”), including outstanding letters of credit of $2.4 million, was $497.6 million. Term Loan At September 30, 2023, we had $81.5 million in borrowings under the Term Loan, of which $2.2 million was classified as current and $79.3 million was classified as long-term. Please refer to Note 9, Derivative Financial Instruments , for a discussion of the foreign currency hedge associated with the Term Loan. Pursuant to the financial covenants in our debt agreements, we are required to maintain established interest coverage ratios and to not exceed established leverage ratios. In addition, the agreements contain other customary covenants, none of which we consider restrictive to our operations. At September 30, 2023, we were in compliance with all of our debt covenants. |
Derivative Financial Instrument
Derivative Financial Instruments | 9 Months Ended |
Sep. 30, 2023 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
Derivative Financial Instruments | Derivative Financial InstrumentsOur ongoing business operations expose us to various risks, such as fluctuating interest rates, foreign currency exchange rates and increasing commodity prices. To manage these market risks, we periodically enter into derivative financial instruments, such as interest rate swaps, options and foreign exchange contracts for periods consistent with, and for notional amounts equal to or less than, the related underlying exposures. We do not purchase or hold any derivative financial instruments for investment or trading purposes. All derivatives are recorded in our condensed consolidated balance sheet at fair value. Foreign Exchange Rate Risk We have entered into forward exchange contracts, designated as fair value hedges, to manage our exposure to fluctuating foreign exchange rates on cross-currency interco mpany loans. As of both September 30, 2023 and December 31, 2022, the notional amount of these forward exchange contracts was Singapore Dollar (“SGD”) 601.5 million and $13.4 million. We have also entered into forward exchange contracts, designated as fair value hedges, to manage our exposure to fluctuating foreign exchange rates on cross-currency intercompany demand notes which were executed in June 2023. As of September 30, 2023, the total amount of these forward exchange contracts was Euro ("EUR") 278.6 million and SGD 94.0 million. In addition, we have entered into several foreign currency contracts, designated as cash flow hedges, for periods of up to eighteen months, intended to hedge the currency risk associated with a portion of our forecasted transactions denominated in foreign currencies. As of September 30, 2023, we had outstanding foreign currency contracts to purchase and sell certain pairs of currencies, as follows: (in millions) Sell Currency Purchase USD Euro EUR 20.3 22.3 — Yen 5,159.3 29.8 9.0 SGD 44.7 15.2 16.8 In December 2019, we entered into a cross-currency swap for $90 million, which we designated as a hedge of our net investment in Daikyo. As of September 30, 2023, the notional amount of the cross-currency swap is ¥8.9 billion ($81.5 million) and the swap termination date is December 31, 2024. Under the cross-currency swap, we receive floating interest rate payments based on USD compounded SOFR plus a margin, in return for paying floating interest rate payments based on Japanese Yen (“Yen”) Tokyo Overnight Average Rate ("TONAR") plus a margin. In addition, we receive periodic fixed principal payments of USD in return for paying fixed principal payments of Yen. Commodity Price Risk Many of our proprietary products are made from synthetic elastomers, which are derived from the petroleum refining process. We purchase the majority of our elastomers via long-term supply contracts, some of which contain clauses that provide for surcharges related to fluctuations in crude oil prices. The following economic hedges did not qualify for hedge accounting treatment since they did not meet the highly effective requirement at inception. From November 2017 through September 2023, we purchased several series of call options for a total of 975,206 barrels of crude oil to mitigate our exposure to such oil-based surcharges and protect operating cash flows with regard to a portion of our forecasted elastomer purchases. As of September 30, 2023, we had outstanding contracts to purchase 229,397 barrels of crude oil from September 2023 to March 2025, at a weighted-average strike price of $94.93 per barrel. Effects of Derivative Instruments on Financial Position and Results of Operations Please refer to Note 10, Fair Value Measurements , for the balance sheet location and fair values of our derivative instruments as of September 30, 2023 and December 31, 2022. The following table summarizes the effects of derivative instruments designated as fair value hedges on the condensed consolidated statements of income: Amount of Gain (Loss) Recognized in Income for the Amount of Gain (Loss) Recognized in Income for the Three Months Ended Nine Months Ended Location on Statement of Income ($ in millions) 2023 2022 2023 2022 Fair Value Hedges: Hedged item (intercompany loan) $ (1.2) $ (14.1) $ 8.7 $ (35.4) Other expense (income) Derivative designated as hedging instrument 0.7 14.1 (10.0) 35.4 Other expense (income) Amount excluded from effectiveness testing (1.5) 2.2 (0.4) 4.4 Other expense (income) Total $ (2.0) $ 2.2 $ (1.7) $ 4.4 We recognize in earnings the initial value of forward point components on a straight-line basis over the life of the fair value hedge. The amounts recognized in earnings, pre-tax, for forward point components for the three and nine months ended September 30, 2023 were $0.2 million and $1.6 million, respectively. The amounts recognized in earnings, pre-tax, for forward point components for the three and nine months ended September 30, 2022 were $1.1 million and $2.8 million, respectively. The following tables summarize the effects of derivative instruments designated as fair value, cash flow, and net investment hedges on other comprehensive income (“OCI”) and earnings, net of tax: Amount of Gain (Loss) Recognized in OCI for the Amount of (Gain) Loss Reclassified from Accumulated OCI into Income for the Location of (Gain) Loss Reclassified from Accumulated OCI into Income Three Months Ended Three Months Ended ($ in millions) 2023 2022 2023 2022 Fair Value Hedges: Foreign currency hedge contracts $ (0.3) $ (0.4) $ 2.3 $ 0.5 Other expense (income) Total $ (0.3) $ (0.4) $ 2.3 $ 0.5 Cash Flow Hedges: Foreign currency hedge contracts $ 0.5 $ 0.7 $ 0.1 $ (0.5) Net sales Foreign currency hedge contracts (2.5) (1.5) 1.1 1.0 Cost of goods and services sold Forward treasury locks — — — 0.1 Interest expense Total $ (2.0) $ (0.8) $ 1.2 $ 0.6 Net Investment Hedges: Cross-currency swap $ 2.9 $ 4.3 $ — $ — Other expense (income) Total $ 2.9 $ 4.3 $ — $ — Amount of Gain (Loss) Recognized in OCI for the Amount of (Gain) Loss Reclassified from Accumulated OCI into Income for the Location of (Gain) Loss Reclassified from Accumulated OCI into Income Nine Months Ended Nine Months Ended ($ in millions) 2023 2022 2023 2022 Fair Value Hedges: Foreign currency hedge contracts $ (2.3) $ 0.3 $ 4.2 $ (0.7) Other expense (income) Total $ (2.3) $ 0.3 $ 4.2 $ (0.7) Cash Flow Hedges: Foreign currency hedge contracts $ (0.4) $ 1.1 $ 1.2 $ (1.1) Net sales Foreign currency hedge contracts (6.1) (4.9) 1.5 2.5 Cost of goods and services sold Forward treasury locks — — 0.1 0.2 Interest expense Total $ (6.5) $ (3.8) $ 2.8 $ 1.6 Net Investment Hedges: Cross-currency swap $ 10.1 $ 13.2 $ — $ — Other expense (income) Total $ 10.1 $ 13.2 $ — $ — Refer to the above table which summarizes the effects of derivative instruments designated as fair value hedges within the other expense (income) line in our condensed consolidated statements of income for the three and nine months ended September 30, 2023 and September 30, 2022. The following table summarizes the effects of derivative instruments designated as cash flow and net investment hedges by line item in our condensed consolidated statements of income: Three Months Ended Nine Months Ended ($ in millions) 2023 2022 2023 2022 Net sales $ 0.1 $ (0.5) $ 1.2 $ (1.1) Cost of goods and services sold 1.1 1.0 1.5 2.5 Interest expense — 0.1 0.1 0.2 The following table summarizes the effects of derivative instruments not designated as hedges on the condensed consolidated statements of income: Amount of (Loss) Gain Recognized in Income for the Amount of Gain (Loss) Recognized in Income for the Three Months Ended Nine Months Ended Location on Statement of Income ($ in millions) 2023 2022 2023 2022 Commodity call options $ 0.5 $ (1.5) $ (0.5) $ 1.6 Other expense (income) Currency Forwards — — (0.2) — Other expense (income) Total $ 0.5 $ (1.5) $ (0.7) $ 1.6 For the three and nine months ended September 30, 2023 and 2022, there was no material ineffectiveness related to our hedges. |
Fair Value Measurements
Fair Value Measurements | 9 Months Ended |
Sep. 30, 2023 | |
Fair Value Disclosures [Abstract] | |
Fair Value Measurements | Fair Value Measurements Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The following fair value hierarchy classifies the inputs to valuation techniques used to measure fair value into one of three levels: • Level 1 : Unadjusted quoted prices in active markets for identical assets or liabilities. • Level 2 : Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. • Level 3 : Unobservable inputs that reflect the reporting entity’s own assumptions. The following tables present the assets and liabilities recorded at fair value on a recurring basis: Balance at Basis of Fair Value Measurements ($ in millions) September 30, Level 1 Level 2 Level 3 Assets: Deferred compensation assets $ 9.1 $ 9.1 $ — $ — Foreign currency contracts 2.4 — 2.4 — Cross-currency swap 22.1 — 22.1 — Commodity call options 1.4 — 1.4 — $ 35.0 $ 9.1 $ 25.9 $ — Liabilities: Contingent consideration $ 4.0 $ — $ — $ 4.0 Deferred compensation liabilities 9.3 9.3 — — Foreign currency contracts 12.1 — 12.1 — $ 25.4 $ 9.3 $ 12.1 $ 4.0 Balance at Basis of Fair Value Measurements ($ in millions) December 31, Level 1 Level 2 Level 3 Assets: Deferred compensation assets $ 12.5 $ 12.5 $ — $ — Foreign currency contracts 4.5 — 4.5 — Cross-currency swap 13.9 — 13.9 — Commodity call options 1.2 1.2 $ 32.1 $ 12.5 $ 19.6 $ — Liabilities: Contingent consideration $ 4.7 $ — $ — $ 4.7 Deferred compensation liabilities 12.7 12.7 — — Foreign currency contracts 1.4 — 1.4 — $ 18.8 $ 12.7 $ 1.4 $ 4.7 Deferred compensation assets are included within other noncurrent assets and are valued using a market approach based on quoted market prices in an active market. The fair value of our foreign currency contracts, included within other current and other noncurrent assets, as well as other current and other long-term liabilities, is valued using an income approach based on quoted forward foreign exchange rates and spot rates at the reporting date. The fair value of the cross-currency swap, included within other noncurrent assets, is valued using a market approach. Please refer to Note 9, Derivative Financial Instruments , for further discussion of our derivatives. The fair value of our commodity call options, included within other current and other noncurrent assets, is valued using a market approach. The fair value of the contingent consideration liability, within current and long-term liabilities, related to the SmartDose ® technology platform (the “SmartDose ® contingent consideration”) was initially determined using a probability-weighted income approach, and is revalued at each reporting date or more frequently if circumstances dictate. Changes in the fair value of this obligation are recorded as income or expense within other expense (income) in our condensed consolidated statements of income. The fair value of deferred compensation liabilities is based on quoted prices of the underlying employees’ investment selections and is included within other long-term liabilities. Other Financial Instruments We believe that the carrying amounts of our cash and cash equivalents and accounts receivable approximate their fair values due to their near-term maturities. The estimated fair value of long-term debt is based on quoted market prices for debt issuances with similar terms and maturities and is classified as Level 2 within the fair value hierarchy. At September 30, 2023, the estimated fair value of long-term debt was $147.2 million compared to a carrying amount of $152.1 million. At December 31, 2022, the estimated fair value of long-term debt was $201.8 million and the carrying amount was $206.7 million. |
Accumulated Other Comprehensive
Accumulated Other Comprehensive Loss | 9 Months Ended |
Sep. 30, 2023 | |
Equity [Abstract] | |
Accumulated Other Comprehensive Loss | Accumulated Other Comprehensive Loss The following table presents the changes in the components of accumulated other comprehensive income ("AOCI") (loss), net of tax, for the nine months ended September 30, 2023: ($ in millions) (Losses) gains on Change in equity affiliate investment AOCI Defined benefit Foreign Total Balance, December 31, 2022 $ 0.2 $ 1.6 $ (9.4) $ (175.4) $ (183.0) Other comprehensive (loss) income before reclassifications (8.8) (0.1) (0.1) (36.9) (45.9) Amounts reclassified out from accumulated other comprehensive (loss) income 7.0 — (1.1) — 5.9 Other comprehensive (loss) income, net of tax (1.8) (0.1) (1.2) (36.9) (40.0) Balance, September 30, 2023 $ (1.6) $ 1.5 $ (10.6) $ (212.3) $ (223.0) The following table presents the changes in the components of accumulated other comprehensive income ("AOCI") (loss), net of tax, for the nine months ended September 30, 2022: ($ in millions) (Losses) gains on Change in equity affiliate investment AOCI Defined benefit Foreign Total Balance, December 31, 2021 $ (1.2) $ 1.5 $ (31.8) $ (128.1) $ (159.6) Other comprehensive (loss) income before reclassifications (3.5) (0.2) 2.9 (162.5) (163.3) Amounts reclassified out from accumulated other comprehensive (loss) income 0.9 — 13.5 — 14.4 Other comprehensive (loss) income, net of tax (2.6) (0.2) 16.4 (162.5) (148.9) Balance, September 30, 2022 $ (3.8) $ 1.3 $ (15.4) $ (290.6) $ (308.5) A summary of the reclassifications out of accumulated other comprehensive loss is presented in the following table: ($ in millions) Three Months Ended Nine Months Ended Location on Statement of Income Detail of components 2023 2022 2023 2022 Gains (losses) on derivatives: Foreign currency contracts $ (0.2) $ 0.5 $ (1.5) $ 1.2 Net sales Foreign currency contracts (1.4) (1.2) (2.0) (2.9) Cost of goods and services sold Foreign currency contracts (3.4) (0.7) (6.2) 1.1 Other expense (income) Forward treasury locks (0.1) (0.1) (0.2) (0.3) Interest expense Total before tax (5.1) (1.5) (9.9) (0.9) Tax benefit (expense) 1.6 0.4 2.9 — Net of tax $ (3.5) $ (1.1) $ (7.0) $ (0.9) Amortization of defined benefit pension and other postretirement plans: Actuarial gains $ 0.3 $ 1.1 $ 1.1 $ 1.1 (a) Settlements — (27.6) — (28.8) (a) Other — — 0.4 (0.4) Total before tax 0.3 (26.5) 1.5 (28.1) Tax (expense) benefit (0.1) 14.2 (0.4) 14.6 Net of tax $ 0.2 $ (12.3) $ 1.1 $ (13.5) Total reclassifications for the period, net of tax $ (3.3) $ (13.4) $ (5.9) $ (14.4) (a) These components are included in the computation of net periodic benefit cost. Please refer to Note 14, Benefit Plans , for additional details. |
Shareholders' Equity
Shareholders' Equity | 9 Months Ended |
Sep. 30, 2023 | |
Equity [Abstract] | |
Shareholders' Equity | Shareholders ’ Equity The following table presents the changes in shareholders’ equity for the nine months ended September 30, 2023: Common Shares Issued Common Stock Capital in Excess of Par Value Number of Treasury Shares Treasury Stock Retained earnings Accumulated other comprehensive loss Total (in millions) Balance, December 31, 2022 75.3 $ 18.8 $ 232.2 1.2 $ (370.9) $ 2,987.8 $ (183.0) $ 2,684.9 Net income — — — — — 140.0 — 140.0 Activity related to stock-based compensation — — (50.8) (0.3) 61.8 — — 11.0 Shares purchased under share repurchase program — — — 0.2 (60.1) — — (60.1) Dividends declared ($0.19 per share) — — — — — (14.2) — (14.2) Other comprehensive income, net of tax — — — — — — 14.6 14.6 Balance, March 31, 2023 75.3 $ 18.8 $ 181.4 1.1 $ (369.2) $ 3,113.6 $ (168.4) $ 2,776.2 Net income — — — — — 155.1 — 155.1 Activity related to stock-based compensation — — (23.2) (0.2) 41.2 — — 18.0 Shares purchased under share repurchase program — — — 0.5 (173.4) — — (173.4) Dividends declared ($0.19 per share) — — — — — (14.1) — (14.1) Other comprehensive loss, net of tax — — — — — — (15.1) (15.1) Balance, June 30, 2023 75.3 $ 18.8 $ 158.2 1.4 $ (501.4) $ 3,254.6 $ (183.5) $ 2,746.7 Net income — — — — — 161.3 — 161.3 Activity related to stock-based compensation — — (35.6) (0.2) 63.1 — — 27.5 Shares purchased under share repurchase program — — — 0.1 (27.8) — — (27.8) Other comprehensive loss, net of tax — — — — — — (39.5) (39.5) Balance, September 30, 2023 75.3 $ 18.8 $ 122.6 1.3 $ (466.1) $ 3,415.9 $ (223.0) $ 2,868.2 The following table presents the changes in shareholders’ equity for the nine months ended September 30, 2022: Common Shares Issued Common Stock Capital in Excess of Par Value Number of Treasury Shares Treasury Stock Retained earnings Accumulated other comprehensive loss Total (in millions) Balance, December 31, 2021 75.3 $ 18.8 $ 249.0 1.1 $ (229.5) $ 2,456.7 $ (159.6) $ 2,335.4 Net income — — — — — 173.8 — 173.8 Activity related to stock-based compensation — — (29.1) (0.3) 29.2 — — 0.1 Shares purchased under share repurchase program — — — 0.4 (147.1) — — (147.1) Dividends declared ($0.18 per share) — — — — — (13.2) — (13.2) Other comprehensive loss, net of tax — — — — — — (22.8) (22.8) Balance, March 31, 2022 75.3 $ 18.8 $ 219.9 1.2 $ (347.4) $ 2,617.3 $ (182.4) $ 2,326.2 Net income — — — — — 188.5 — 188.5 Activity related to stock-based compensation — — 5.4 — 9.7 — — 15.1 Shares purchased under share repurchase program — — — 0.1 (28.6) — — (28.6) Dividends declared ($0.18 per share) — — — — — (13.3) — (13.3) Other comprehensive loss, net of tax — — — — — — (63.5) (63.5) Balance, June 30, 2022 75.3 $ 18.8 $ 225.3 1.3 $ (366.3) $ 2,792.5 $ (245.9) $ 2,424.4 Net income — — — — — 120.6 — 120.6 Activity related to stock-based compensation — — 5.3 (0.1) 10.3 — — 15.6 Shares purchased under share repurchase program — — — 0.1 (27.2) — — (27.2) Other comprehensive loss, net of tax — — — — — — (62.6) (62.6) Balance, September 30, 2022 75.3 $ 18.8 $ 230.6 1.3 $ (383.2) $ 2,913.1 $ (308.5) $ 2,470.8 |
Stock-Based Compensation
Stock-Based Compensation | 9 Months Ended |
Sep. 30, 2023 | |
Share-Based Payment Arrangement [Abstract] | |
Stock-Based Compensation | Stock-Based Compensation The West Pharmaceutical Services, Inc. 2016 Omnibus Incentive Compensation Plan (the “2016 Plan”) provides for the granting of stock options, stock appreciation rights, restricted stock awards and performance awards to employees and non-employee directors. A committee of the Board of Directors determines the terms and conditions of awards to be granted. Vesting requirements vary by award. At September 30, 2023, there were 1,438,454 shares remaining in the 2016 Plan for future grants. During the nine months ended September 30, 2023, we granted 105,640 stock options at a weighted average exercise price of $306.92 per share based on the grant-date fair value of our stock to employees under the 2016 Plan. The weighted average grant date fair value of options granted was $108.88 per share as determined by the Black-Scholes option valuation model using the following weighted average assumptions: a risk-free interest rate of 4.1%; expected life of 5.7 years based on prior experience; stock volatility of 29.8% based on historical data; and a dividend yield of 0.3%. Stock option expense is recognized over the vesting period, net of forfeitures. During the nine months ended September 30, 2023, we granted 37,536 stock-settled performance share unit (“PSU”) awards at a weighted average grant-date fair value of $306.91 per share to eligible employees. These awards are earned based on the Company’s performance against pre-established targets, including annual growth rate of revenue and return on invested capital, over a specified performance period. Depending on the achievement of the targets, recipients of stock-settled PSU awards are entitled to receive a certain number of shares of common stock. Shares earned under PSU awards may vary from 0% to 200% of an employee’s targeted award. The fair value of stock-settled PSU awards is based on the market price of our stock at the grant date and is recognized as expense over the performance period, adjusted for estimated target outcomes and net of forfeitures. During the nine months ended September 30, 2023, we granted 4,563 stock-settled restricted share unit (“RSU”) awards at a weighted average grant-date fair value of $310.56 per share to eligible employees. These awards are earned over a specified performance period. The fair value of stock-settled RSU awards is based on the market price of our stock at the grant date and is recognized as expense over the vesting period, net of forfeitures. |
Benefit Plans
Benefit Plans | 9 Months Ended |
Sep. 30, 2023 | |
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract] | |
Benefit Plans | Benefit Plans The components of net periodic benefit cost for the three months ended September 30 were as follows: Pension benefits Other retirement benefits Total ($ in millions) 2023 2022 2023 2022 2023 2022 Service cost $ 0.2 $ 0.3 $ — $ — $ 0.2 $ 0.3 Interest cost 0.6 0.5 0.1 0.1 0.7 0.6 Expected return on assets (0.4) (0.8) — — (0.4) (0.8) Recognized actuarial losses (gains) 0.2 0.3 (0.5) (0.4) (0.3) (0.1) Settlements — 49.6 — — — 49.6 Net periodic benefit cost $ 0.6 $ 49.9 $ (0.4) $ (0.3) $ 0.2 $ 49.6 Pension benefits Other retirement benefits Total ($ in millions) 2023 2022 2023 2022 2023 2022 U.S. plans $ — $ 49.6 $ (0.4) $ (0.3) $ (0.4) $ 49.3 International plans 0.6 0.3 — — 0.6 0.3 Net periodic benefit cost $ 0.6 $ 49.9 $ (0.4) $ (0.3) $ 0.2 $ 49.6 The components of net periodic benefit cost for the nine months ended September 30 were as follows: Pension benefits Other retirement benefits Total ($ in millions) 2023 2022 2023 2022 2023 2022 Service cost $ 0.8 $ 1.0 $ — $ — $ 0.8 $ 1.0 Interest cost 1.8 3.7 0.2 0.1 2.0 3.8 Expected return on assets (1.0) (5.4) — — (1.0) (5.4) Recognized actuarial losses (gains) 0.5 1.0 (1.6) (1.1) (1.1) (0.1) Settlements — 50.8 — — — 50.8 Net periodic benefit cost $ 2.1 $ 51.1 $ (1.4) $ (1.0) $ 0.7 $ 50.1 Pension benefits Other retirement benefits Total ($ in millions) 2023 2022 2023 2022 2023 2022 U.S. plans $ 0.3 $ 50.3 $ (1.4) $ (1.0) $ (1.1) $ 49.3 International plans 1.8 0.8 — — 1.8 0.8 Net periodic benefit cost $ 2.1 $ 51.1 $ (1.4) $ (1.0) $ 0.7 $ 50.1 During 2021, the Company approved the termination of our U.S. qualified defined benefit pension plan (the "U.S. pension plan"). Prior to the third quarter of 2022, a Notice of Intent to Terminate was sent to all interested parties and a favorable determination letter was received from the Internal Revenue Service. During the three months ended September 30, 2022, lump sum payments were offered to all current employees and former employees with vested benefits under the U.S. pension plan. A cash contribution of $6.5 million was then made by the Company to ensure the U.S. pension plan was fully funded in preparation for the group annuity contract purchase which was executed in August of 2022 to settle the outstanding benefit obligations. During the three and nine months ended September 30, 2022, we recorded $49.6 million and $50.8 million in pension settlement charges, respectively, within other nonoperating (income) expense, which for the nine months ended September 30, 2022 relieved the historical balance sheet position, inclusive of accumulated other comprehensive income, of the U.S. pension plan. |
Other Expense (Income)
Other Expense (Income) | 9 Months Ended |
Sep. 30, 2023 | |
Other Income and Expenses [Abstract] | |
Other Expense (Income) | Other Expense (Income) Other expense (income) consists of: Three Months Ended Nine Months Ended ($ in millions) 2023 2022 2023 2022 Loss on disposal of plant $ — $ — $ 11.6 $ — Asset impairments 3.5 1.4 6.9 1.6 Restructuring and related charges — — (0.8) (1.6) (Gain) loss on oil hedges (0.5) 1.5 0.5 (1.6) Contingent consideration 0.7 1.5 1.5 2.6 Foreign exchange transaction losses (gains) 1.8 (2.2) 3.0 (4.6) Other items 0.1 (0.3) (0.2) (0.4) Total other expense (income) $ 5.6 $ 1.9 $ 22.5 $ (4.0) Loss on Disposal of Plant During the nine months ended September 30, 2023, the Company recorded expense of $11.6 million, respectively, within other expense (income), as a result of the sale of one of the Company’s manufacturing facilities within the Proprietary Products segment. The transaction closed during the second quarter of 2023. Restructuring and Related Charges In December 2022, the Company approved a restructuring plan to adjust our operating cost base to better respond to the macroeconomic factors influencing our business. These changes are expected to be implemented over a period of up to twenty-four months from the date of approval. The plan is expected to require restructuring and related charges of approximately $25 million to $27 million, with annualized savings in the range of $22 million to $24 million. The following table presents activity related to our restructuring obligations related to our 2022 restructuring plan: ($ in millions) Severance Other charges Total Balance, December 31, 2022 $ 10.1 $ 15.3 $ 25.4 (Credits) Charges (0.8) — (0.8) Cash payments (3.7) — (3.7) Non-cash asset write downs — (15.3) (15.3) Balance, September 30, 2023 $ 5.6 $ — $ 5.6 Oil Hedges During the three and nine months ended September 30, 2023, we recorded a gain of $0.5 million and a loss of $0.5 million, respectively, related to oil hedges. During the three and nine months ended September 30, 2022, we recorded a loss of $1.5 million and a gain of $1.6 million, respectively, related to oil hedges. Please refer to Note 9, Derivative Financial Instruments , for further discussion of our hedging activity. Contingent Consideration Contingent consideration represents changes in the fair value of the SmartDose ® contingent consideration. Please refer to Note 10, Fair Value Measurements |
Income Taxes
Income Taxes | 9 Months Ended |
Sep. 30, 2023 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | Income Taxes The tax provision for interim periods is determined using the estimated annual effective consolidated tax rate, based on the current estimate of full-year earnings before taxes, adjusted for the impact of discrete quarterly items. The provision for income taxes was $29.4 million and $20.4 million for the three months ended September 30, 2023 and 2022, respectively, and the effective tax rate was 15.7% and 15.0%, respectively. The increase in the effective tax rate is primarily due to a t ax benefit of $20.0 million related to the termination of the U.S. pension plan recorded in the three months ended September 30, 2022 that was not repeated in the same period in 2023. This was offset by an increase in the tax benefit related to stock-based compensation in the three months ended September 30, 2023, as compared to the same period in 2022 . The provision for income taxes was $87.8 million and $85.8 million for the nine months ended September 30, 2023 and 2022, respectively, and the effective tax rate was 16.6% and 15.6%, respectively. The increase in the effective tax rate is primarily due to a t ax benefit of $20.3 million related to the termination of the U.S. pension plan recorded in the nine months ended September 30, 2022 and a $5.9 million tax benefit recorded as the result of a state tax valuation allowance reversal in the nine months ended September 30, 2022 that were not repeated in the same period in 2023. This was offset by an increase in the tax benefit related to stock-based compensation in the nine months ended September 30, 2023, as compared to the same period in 2022 . |
Commitments and Contingencies
Commitments and Contingencies | 9 Months Ended |
Sep. 30, 2023 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | Commitments and Contingencies From time to time, we are involved in product liability matters and other legal proceedings and claims generally incidental to our normal business activities. We accrue for loss contingencies when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. While the outcome of current proceedings cannot be accurately predicted, we believe their ultimate resolution should not have a material adverse effect on our business, financial condition, results of operations or liquidity. There have been no significant changes to the commitments and contingencies included in our 2022 Annual Report . |
Segment Information
Segment Information | 9 Months Ended |
Sep. 30, 2023 | |
Segment Reporting [Abstract] | |
Segment Information | Segment Information Our business operations are organized into two reportable segments, Proprietary Products and Contract-Manufactured Products. Our Proprietary Products reportable segment offers proprietary packaging, containment solutions and drug delivery products, along with analytical lab services and other integrated services and solutions, primarily to biologic, generic and pharmaceutical drug customers. Our Contract-Manufactured Products reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. The Chief Operating Decision Maker ("CODM") evaluates the performance of our segments based upon, among other things, segment net sales and operating profit. Segment operating profit excludes general corporate costs, which include executive and director compensation, stock-based compensation, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments. Also excluded are items that the CODM considers not representative of ongoing operations. Such items are referred to as other unallocated items and generally include restructuring and related charges, certain asset impairments and other specifically-identified income or expense items. The segment operating profit metric is what the CODM uses in evaluating our results of operations and the financial measure that provides a valuable insight into our overall performance and financial position. The following table presents information about our reportable segments, reconciled to consolidated totals: Three Months Ended Nine Months Ended ($ in millions) 2023 2022 2023 2022 Net sales: Proprietary Products $ 602.5 $ 567.0 $ 1,803.6 $ 1,822.0 Contract-Manufactured Products 144.9 120.0 414.2 356.5 Intersegment sales elimination — (0.1) — (0.3) Consolidated net sales $ 747.4 $ 686.9 $ 2,217.8 $ 2,178.2 The intersegment sales elimination, which is required for the presentation of consolidated net sales, represents the elimination of components sold between our segments. The following table provides summarized financial information for our segments: Three Months Ended Nine Months Ended ($ in millions) 2023 2022 2023 2022 Operating profit (loss): Proprietary Products $ 181.6 $ 188.6 $ 546.5 $ 615.9 Contract-Manufactured Products 21.0 14.7 53.3 48.0 Total business segment operating profit $ 202.6 $ 203.3 $ 599.8 $ 663.9 Corporate and Unallocated Stock-based compensation expense $ (5.9) $ (6.0) $ (21.9) $ (17.0) Corporate general costs (1) (15.9) (10.9) (47.2) (43.6) Unallocated Items: Loss on disposal of plant (2) — — (11.6) — Cost investment impairment (3) (3.3) — (3.3) — Restructuring and other charges (4) — — (0.1) 1.6 Amortization of acquisition-related intangible assets (5) (0.2) (0.2) (0.6) (0.6) Total Corporate and Unallocated (25.3) (17.1) (84.7) (59.6) Total consolidated operating profit $ 177.3 $ 186.2 $ 515.1 $ 604.3 Interest (income) expense and other nonoperating (income) expense, net (9.7) 50.0 (14.7) 53.1 Income before income taxes and equity in net income of affiliated companies $ 187.0 $ 136.2 $ 529.8 $ 551.2 (1) Corporate general costs includes executive and director compensation, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments. (2) During the nine months ended September 30, 2023, the Company recorded expense of $11.6 million within other expense (income), as a result of the sale of one of the Company’s manufacturing facilities within the Proprietary Products segment. The transaction closed during the second quarter of 2023. (3) During the three and nine months ended September 30, 2023, the Company recorded expense of $3.3 million within other expense (income), as a result of an impairment of one of the Company's cost investments. (4) Restructuring and other charges of $0.1 million for the nine months ended September 30, 2023 represents the net impact of an inventory write down of $0.9 million within cost of goods and services sold and a $0.8 million benefit within other expense (income) for revised severance estimates in connection with its 2022 restructuring plan. During the nine months ended September 30, 2022, the Company recorded a benefit within other expense (income) of $1.6 million for restructuring and severance related costs in connection with its 2020 plan related to revised severance estimates. (5) During the three and nine months ended September 30, 2023, the Company recorded $0.2 million and $0.6 million, respectively, of amortization expense within operating profit associated with an intangible asset acquired during the second quarter of 2020. During the three and nine months ended September 30, 2022, the Company recorded $0.2 million and $0.6 million, respectively, of amortization expense within operating profit associated with an intangible asset acquired during the second quarter of 2020. Please refer to Note 15, Other Expense (Income) , for further discussion of these items. |
Pay vs Performance Disclosure
Pay vs Performance Disclosure - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | ||||||
Sep. 30, 2023 | Jun. 30, 2023 | Mar. 31, 2023 | Sep. 30, 2022 | Jun. 30, 2022 | Mar. 31, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Pay vs Performance Disclosure | ||||||||
Net income | $ 161.3 | $ 155.1 | $ 140 | $ 120.6 | $ 188.5 | $ 173.8 | $ 456.4 | $ 482.9 |
Insider Trading Arrangements
Insider Trading Arrangements | 3 Months Ended | 9 Months Ended |
Sep. 30, 2023 shares | Sep. 30, 2023 shares | |
Trading Arrangements, by Individual | ||
Rule 10b5-1 Arrangement Adopted | false | |
Non-Rule 10b5-1 Arrangement Adopted | false | |
Rule 10b5-1 Arrangement Terminated | false | |
Non-Rule 10b5-1 Arrangement Terminated | false | |
Eric M. Green [Member] | ||
Trading Arrangements, by Individual | ||
Material Terms of Trading Arrangement | Eric M. Green, President and Chief Executive Officer, Chair of the Board of Directors, entered into a prearranged stock trading arrangement on May 5, 2023. Mr. Green’s plan provides for the purchase and sale of an aggregate number of 234,864 shares of the Company's common stock (of which Mr. Green will sell 204,864 shares and retain the rest immediately following the exercise) between August 8, 2023 and August 6, 2024. The trading plan was entered into during an open insider trading window and is intended to satisfy Rule 10b5-1(c) under the Exchange Act and the Company’s policies regarding insider transactions. | |
Name | Eric M. Green | |
Title | President and Chief Executive Officer, Chair of the Board of Directors | |
Adoption Date | May 5, 2023 | |
Arrangement Duration | 364 days | |
Aggregate Available | 234,864 | 234,864 |
Basis of Presentation and Sum_2
Basis of Presentation and Summary of Significant Accounting Policies (Policies) | 9 Months Ended |
Sep. 30, 2023 | |
Accounting Policies [Abstract] | |
Basis of Presentation | Basis of Presentation : The condensed consolidated financial statements included in this report are unaudited and have been prepared in accordance with United States (“U.S.”) generally accepted accounting principles (“U.S. GAAP”) for interim financial reporting and U.S. Securities and Exchange Commission (“SEC”) regulations. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, these financial statements include all adjustments, which are of a normal recurring nature, necessary for a fair statement of the financial position, results of operations, cash flows and the change in equity for the periods presented. The condensed consolidated financial statements for the three and nine months ended September 30, 2023, should be read in conjunction with the consolidated financial statements and notes thereto of West Pharmaceutical Services, Inc. and its majority-owned subsidiaries (which may be referred to as “West”, the “Company”, “we”, “us” or “our”) appearing in our Annual Report on Form 10-K for the year ended December 31, 2022 (the “ 2022 Annual Report ”). The results of operations for any interim period are not necessarily indicative of results for the full year. |
New Accounting Standards | New Accounting Standards Recently Adopted Standards In September 2022, the Financial Accounting Standards Board ("FASB") issued guidance that seeks to enhance transparency around entities' use of supplier finance programs. The amendment requires the buyer in a supplier finance program to disclose information about the key terms of the program, outstanding confirmed amounts as of the end of the period, a rollforward of such amounts during each annual period, and a description of where in the financial statements outstanding amounts are presented. This guidance is effective for fiscal years beginning after December 15, 2022. We adopted this guidance as of January 1, 2023, on a prospective basis. The adoption did not have a material impact on our financial statements, as supplier finance programs are not material to the Company as of September 30, 2023. |
Revenue (Tables)
Revenue (Tables) | 9 Months Ended |
Sep. 30, 2023 | |
Revenue from Contract with Customer [Abstract] | |
Schedule of Disaggregation of Revenue | The following table presents the approximate percentage of our net sales by market group: Three Months Ended Nine Months Ended 2023 2022 2023 2022 Biologics 40 % 41 % 37 % 42 % Generics 19 % 18 % 20 % 18 % Pharma 22 % 24 % 24 % 24 % Contract-Manufactured Products 19 % 17 % 19 % 16 % 100 % 100 % 100 % 100 % The following table presents the approximate percentage of our net sales by product category: Three Months Ended Nine Months Ended 2023 2022 2023 2022 High-Value Product Components 50 % 54 % 50 % 56 % High-Value Product Delivery Devices 11 % 6 % 10 % 5 % Standard Packaging 20 % 23 % 21 % 23 % Contract-Manufactured Products 19 % 17 % 19 % 16 % 100 % 100 % 100 % 100 % Due to the Company's reassessment of product categories, beginning in the second quarter of 2023, certain product types have been moved from High-Value Product Components to High-Value Product Delivery Devices. No adjustments were made to the product categorization prior to the second quarter of 2023. The following table presents the approximate percentage of our net sales by geographic location: Three Months Ended Nine Months Ended 2023 2022 2023 2022 Americas 46 % 53 % 45 % 48 % Europe, Middle East, Africa 46 % 38 % 46 % 43 % Asia Pacific 8 % 9 % 9 % 9 % 100 % 100 % 100 % 100 % |
Schedule of Change in Contract with Customer, Asset and Liability | The following table summarizes our contract assets and liabilities, excluding amounts included in accounts receivable, net: ($ in millions) Contract assets, December 31, 2022 $ 16.3 Contract assets, September 30, 2023 19.9 Change in contract assets - increase (decrease) $ 3.6 Deferred income, December 31, 2022 $ (68.2) Deferred income, September 30, 2023 (50.0) Change in deferred income - decrease (increase) $ 18.2 |
Net Income Per Share (Tables)
Net Income Per Share (Tables) | 9 Months Ended |
Sep. 30, 2023 | |
Earnings Per Share [Abstract] | |
Schedule of Reconciliation of Basic to Diluted Net Income Per Share | The following table reconciles the shares used in the calculation of basic net income per share to those used for diluted net income per share: Three Months Ended Nine Months Ended (in millions) 2023 2022 2023 2022 Net income $ 161.3 $ 120.6 $ 456.4 $ 482.9 Weighted average common shares outstanding 74.3 74.4 74.4 74.4 Dilutive effect of equity awards, based on the treasury stock method 1.0 1.3 1.1 1.5 Weighted average shares assuming dilution 75.3 75.7 75.5 75.9 |
Inventories (Tables)
Inventories (Tables) | 9 Months Ended |
Sep. 30, 2023 | |
Inventory Disclosure [Abstract] | |
Schedule of Inventories | Inventories are valued at the lower of cost (on a first-in, first-out basis) or net realizable value. Inventory balances were as follows: ($ in millions) September 30, December 31, Raw materials $ 180.2 $ 170.7 Work in process 93.8 79.0 Finished goods 157.8 165.1 $ 431.8 $ 414.8 |
Leases (Tables)
Leases (Tables) | 9 Months Ended |
Sep. 30, 2023 | |
Leases [Abstract] | |
Schedule of Lease Expense | The components of lease expense were as follows: Three Months Ended Nine Months Ended ($ in millions) 2023 2022 2023 2022 Operating lease cost $ 4.3 $ 3.7 $ 15.0 $ 10.4 Short-term lease cost 1.9 0.3 4.4 1.1 Variable lease cost 1.4 2.3 4.4 4.7 Total lease cost $ 7.6 $ 6.3 $ 23.8 $ 16.2 |
Schedule of Supplemental Cash Flow Information Related to Leases | Supplemental cash flow information related to leases were as follows: Three Months Ended Nine Months Ended ($ in millions) 2023 2022 2023 2022 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 4.5 $ 3.7 $ 14.4 $ 10.0 Right-of-use assets obtained in exchange for new operating lease liabilities $ 3.1 $ 14.0 $ 6.6 $ 29.5 |
Schedule of Maturities of Operating Lease Liabilities | Maturities of operating lease liabilities were as follows: ($ in millions) September 30, December 31, Year 2023 2022 2023 (remaining period as of) $ 4.8 $ 19.0 2024 19.1 18.1 2025 17.1 16.0 2026 14.1 13.4 2027 9.8 9.4 Thereafter 50.6 50.8 115.5 126.7 Less: imputed lease interest (16.0) (17.7) Total lease liabilities $ 99.5 $ 109.0 |
Debt (Tables)
Debt (Tables) | 9 Months Ended |
Sep. 30, 2023 | |
Debt Disclosure [Abstract] | |
Schedule of Long-term Debt Obligations, Net of Unamortized Debt Issuance Costs and Current Maturities | The following table summarizes our long-term debt obligations, net of unamortized debt issuance costs and current maturities. The interest rates shown in parentheses are as of September 30, 2023. ($ in millions) September 30, December 31, Term Loan, due December 31, 2024 (6.37%) $ 81.5 $ 83.2 Series B notes, due July 5, 2024 (3.82%) 53.0 53.0 Series C notes, due July 5, 2027 (4.02%) 73.0 73.0 207.5 209.2 Less: unamortized debt issuance costs 0.2 0.3 Total debt 207.3 208.9 Less: current portion of long-term debt 55.2 2.2 Long-term debt, net $ 152.1 $ 206.7 |
Derivative Financial Instrume_2
Derivative Financial Instruments (Tables) | 9 Months Ended |
Sep. 30, 2023 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
Schedule of Foreign Currency Contracts | As of September 30, 2023, we had outstanding foreign currency contracts to purchase and sell certain pairs of currencies, as follows: (in millions) Sell Currency Purchase USD Euro EUR 20.3 22.3 — Yen 5,159.3 29.8 9.0 SGD 44.7 15.2 16.8 |
Schedule of Effects of Derivative Instruments on Other Comprehensive Income ('OCI') and Earnings | The following table summarizes the effects of derivative instruments designated as fair value hedges on the condensed consolidated statements of income: Amount of Gain (Loss) Recognized in Income for the Amount of Gain (Loss) Recognized in Income for the Three Months Ended Nine Months Ended Location on Statement of Income ($ in millions) 2023 2022 2023 2022 Fair Value Hedges: Hedged item (intercompany loan) $ (1.2) $ (14.1) $ 8.7 $ (35.4) Other expense (income) Derivative designated as hedging instrument 0.7 14.1 (10.0) 35.4 Other expense (income) Amount excluded from effectiveness testing (1.5) 2.2 (0.4) 4.4 Other expense (income) Total $ (2.0) $ 2.2 $ (1.7) $ 4.4 The following tables summarize the effects of derivative instruments designated as fair value, cash flow, and net investment hedges on other comprehensive income (“OCI”) and earnings, net of tax: Amount of Gain (Loss) Recognized in OCI for the Amount of (Gain) Loss Reclassified from Accumulated OCI into Income for the Location of (Gain) Loss Reclassified from Accumulated OCI into Income Three Months Ended Three Months Ended ($ in millions) 2023 2022 2023 2022 Fair Value Hedges: Foreign currency hedge contracts $ (0.3) $ (0.4) $ 2.3 $ 0.5 Other expense (income) Total $ (0.3) $ (0.4) $ 2.3 $ 0.5 Cash Flow Hedges: Foreign currency hedge contracts $ 0.5 $ 0.7 $ 0.1 $ (0.5) Net sales Foreign currency hedge contracts (2.5) (1.5) 1.1 1.0 Cost of goods and services sold Forward treasury locks — — — 0.1 Interest expense Total $ (2.0) $ (0.8) $ 1.2 $ 0.6 Net Investment Hedges: Cross-currency swap $ 2.9 $ 4.3 $ — $ — Other expense (income) Total $ 2.9 $ 4.3 $ — $ — Amount of Gain (Loss) Recognized in OCI for the Amount of (Gain) Loss Reclassified from Accumulated OCI into Income for the Location of (Gain) Loss Reclassified from Accumulated OCI into Income Nine Months Ended Nine Months Ended ($ in millions) 2023 2022 2023 2022 Fair Value Hedges: Foreign currency hedge contracts $ (2.3) $ 0.3 $ 4.2 $ (0.7) Other expense (income) Total $ (2.3) $ 0.3 $ 4.2 $ (0.7) Cash Flow Hedges: Foreign currency hedge contracts $ (0.4) $ 1.1 $ 1.2 $ (1.1) Net sales Foreign currency hedge contracts (6.1) (4.9) 1.5 2.5 Cost of goods and services sold Forward treasury locks — — 0.1 0.2 Interest expense Total $ (6.5) $ (3.8) $ 2.8 $ 1.6 Net Investment Hedges: Cross-currency swap $ 10.1 $ 13.2 $ — $ — Other expense (income) Total $ 10.1 $ 13.2 $ — $ — Refer to the above table which summarizes the effects of derivative instruments designated as fair value hedges within the other expense (income) line in our condensed consolidated statements of income for the three and nine months ended September 30, 2023 and September 30, 2022. The following table summarizes the effects of derivative instruments designated as cash flow and net investment hedges by line item in our condensed consolidated statements of income: Three Months Ended Nine Months Ended ($ in millions) 2023 2022 2023 2022 Net sales $ 0.1 $ (0.5) $ 1.2 $ (1.1) Cost of goods and services sold 1.1 1.0 1.5 2.5 Interest expense — 0.1 0.1 0.2 |
Schedule of Derivative Instruments Not Designated as Hedges | The following table summarizes the effects of derivative instruments not designated as hedges on the condensed consolidated statements of income: Amount of (Loss) Gain Recognized in Income for the Amount of Gain (Loss) Recognized in Income for the Three Months Ended Nine Months Ended Location on Statement of Income ($ in millions) 2023 2022 2023 2022 Commodity call options $ 0.5 $ (1.5) $ (0.5) $ 1.6 Other expense (income) Currency Forwards — — (0.2) — Other expense (income) Total $ 0.5 $ (1.5) $ (0.7) $ 1.6 |
Fair Value Measurements (Tables
Fair Value Measurements (Tables) | 9 Months Ended |
Sep. 30, 2023 | |
Fair Value Disclosures [Abstract] | |
Schedule of Assets and Liabilities Measured at Fair Value | The following tables present the assets and liabilities recorded at fair value on a recurring basis: Balance at Basis of Fair Value Measurements ($ in millions) September 30, Level 1 Level 2 Level 3 Assets: Deferred compensation assets $ 9.1 $ 9.1 $ — $ — Foreign currency contracts 2.4 — 2.4 — Cross-currency swap 22.1 — 22.1 — Commodity call options 1.4 — 1.4 — $ 35.0 $ 9.1 $ 25.9 $ — Liabilities: Contingent consideration $ 4.0 $ — $ — $ 4.0 Deferred compensation liabilities 9.3 9.3 — — Foreign currency contracts 12.1 — 12.1 — $ 25.4 $ 9.3 $ 12.1 $ 4.0 Balance at Basis of Fair Value Measurements ($ in millions) December 31, Level 1 Level 2 Level 3 Assets: Deferred compensation assets $ 12.5 $ 12.5 $ — $ — Foreign currency contracts 4.5 — 4.5 — Cross-currency swap 13.9 — 13.9 — Commodity call options 1.2 1.2 $ 32.1 $ 12.5 $ 19.6 $ — Liabilities: Contingent consideration $ 4.7 $ — $ — $ 4.7 Deferred compensation liabilities 12.7 12.7 — — Foreign currency contracts 1.4 — 1.4 — $ 18.8 $ 12.7 $ 1.4 $ 4.7 |
Accumulated Other Comprehensi_2
Accumulated Other Comprehensive Loss (Tables) | 9 Months Ended |
Sep. 30, 2023 | |
Equity [Abstract] | |
Schedule of Components of Accumulated Other Comprehensive Income ("AOCI") (Loss) | The following table presents the changes in the components of accumulated other comprehensive income ("AOCI") (loss), net of tax, for the nine months ended September 30, 2023: ($ in millions) (Losses) gains on Change in equity affiliate investment AOCI Defined benefit Foreign Total Balance, December 31, 2022 $ 0.2 $ 1.6 $ (9.4) $ (175.4) $ (183.0) Other comprehensive (loss) income before reclassifications (8.8) (0.1) (0.1) (36.9) (45.9) Amounts reclassified out from accumulated other comprehensive (loss) income 7.0 — (1.1) — 5.9 Other comprehensive (loss) income, net of tax (1.8) (0.1) (1.2) (36.9) (40.0) Balance, September 30, 2023 $ (1.6) $ 1.5 $ (10.6) $ (212.3) $ (223.0) The following table presents the changes in the components of accumulated other comprehensive income ("AOCI") (loss), net of tax, for the nine months ended September 30, 2022: ($ in millions) (Losses) gains on Change in equity affiliate investment AOCI Defined benefit Foreign Total Balance, December 31, 2021 $ (1.2) $ 1.5 $ (31.8) $ (128.1) $ (159.6) Other comprehensive (loss) income before reclassifications (3.5) (0.2) 2.9 (162.5) (163.3) Amounts reclassified out from accumulated other comprehensive (loss) income 0.9 — 13.5 — 14.4 Other comprehensive (loss) income, net of tax (2.6) (0.2) 16.4 (162.5) (148.9) Balance, September 30, 2022 $ (3.8) $ 1.3 $ (15.4) $ (290.6) $ (308.5) |
Schedule of Reclassification Out of Accumulated Other Comprehensive Loss | A summary of the reclassifications out of accumulated other comprehensive loss is presented in the following table: ($ in millions) Three Months Ended Nine Months Ended Location on Statement of Income Detail of components 2023 2022 2023 2022 Gains (losses) on derivatives: Foreign currency contracts $ (0.2) $ 0.5 $ (1.5) $ 1.2 Net sales Foreign currency contracts (1.4) (1.2) (2.0) (2.9) Cost of goods and services sold Foreign currency contracts (3.4) (0.7) (6.2) 1.1 Other expense (income) Forward treasury locks (0.1) (0.1) (0.2) (0.3) Interest expense Total before tax (5.1) (1.5) (9.9) (0.9) Tax benefit (expense) 1.6 0.4 2.9 — Net of tax $ (3.5) $ (1.1) $ (7.0) $ (0.9) Amortization of defined benefit pension and other postretirement plans: Actuarial gains $ 0.3 $ 1.1 $ 1.1 $ 1.1 (a) Settlements — (27.6) — (28.8) (a) Other — — 0.4 (0.4) Total before tax 0.3 (26.5) 1.5 (28.1) Tax (expense) benefit (0.1) 14.2 (0.4) 14.6 Net of tax $ 0.2 $ (12.3) $ 1.1 $ (13.5) Total reclassifications for the period, net of tax $ (3.3) $ (13.4) $ (5.9) $ (14.4) (a) These components are included in the computation of net periodic benefit cost. Please refer to Note 14, Benefit Plans , for additional details. |
Shareholders' Equity (Tables)
Shareholders' Equity (Tables) | 9 Months Ended |
Sep. 30, 2023 | |
Equity [Abstract] | |
Schedule of Stockholders Equity | The following table presents the changes in shareholders’ equity for the nine months ended September 30, 2023: Common Shares Issued Common Stock Capital in Excess of Par Value Number of Treasury Shares Treasury Stock Retained earnings Accumulated other comprehensive loss Total (in millions) Balance, December 31, 2022 75.3 $ 18.8 $ 232.2 1.2 $ (370.9) $ 2,987.8 $ (183.0) $ 2,684.9 Net income — — — — — 140.0 — 140.0 Activity related to stock-based compensation — — (50.8) (0.3) 61.8 — — 11.0 Shares purchased under share repurchase program — — — 0.2 (60.1) — — (60.1) Dividends declared ($0.19 per share) — — — — — (14.2) — (14.2) Other comprehensive income, net of tax — — — — — — 14.6 14.6 Balance, March 31, 2023 75.3 $ 18.8 $ 181.4 1.1 $ (369.2) $ 3,113.6 $ (168.4) $ 2,776.2 Net income — — — — — 155.1 — 155.1 Activity related to stock-based compensation — — (23.2) (0.2) 41.2 — — 18.0 Shares purchased under share repurchase program — — — 0.5 (173.4) — — (173.4) Dividends declared ($0.19 per share) — — — — — (14.1) — (14.1) Other comprehensive loss, net of tax — — — — — — (15.1) (15.1) Balance, June 30, 2023 75.3 $ 18.8 $ 158.2 1.4 $ (501.4) $ 3,254.6 $ (183.5) $ 2,746.7 Net income — — — — — 161.3 — 161.3 Activity related to stock-based compensation — — (35.6) (0.2) 63.1 — — 27.5 Shares purchased under share repurchase program — — — 0.1 (27.8) — — (27.8) Other comprehensive loss, net of tax — — — — — — (39.5) (39.5) Balance, September 30, 2023 75.3 $ 18.8 $ 122.6 1.3 $ (466.1) $ 3,415.9 $ (223.0) $ 2,868.2 The following table presents the changes in shareholders’ equity for the nine months ended September 30, 2022: Common Shares Issued Common Stock Capital in Excess of Par Value Number of Treasury Shares Treasury Stock Retained earnings Accumulated other comprehensive loss Total (in millions) Balance, December 31, 2021 75.3 $ 18.8 $ 249.0 1.1 $ (229.5) $ 2,456.7 $ (159.6) $ 2,335.4 Net income — — — — — 173.8 — 173.8 Activity related to stock-based compensation — — (29.1) (0.3) 29.2 — — 0.1 Shares purchased under share repurchase program — — — 0.4 (147.1) — — (147.1) Dividends declared ($0.18 per share) — — — — — (13.2) — (13.2) Other comprehensive loss, net of tax — — — — — — (22.8) (22.8) Balance, March 31, 2022 75.3 $ 18.8 $ 219.9 1.2 $ (347.4) $ 2,617.3 $ (182.4) $ 2,326.2 Net income — — — — — 188.5 — 188.5 Activity related to stock-based compensation — — 5.4 — 9.7 — — 15.1 Shares purchased under share repurchase program — — — 0.1 (28.6) — — (28.6) Dividends declared ($0.18 per share) — — — — — (13.3) — (13.3) Other comprehensive loss, net of tax — — — — — — (63.5) (63.5) Balance, June 30, 2022 75.3 $ 18.8 $ 225.3 1.3 $ (366.3) $ 2,792.5 $ (245.9) $ 2,424.4 Net income — — — — — 120.6 — 120.6 Activity related to stock-based compensation — — 5.3 (0.1) 10.3 — — 15.6 Shares purchased under share repurchase program — — — 0.1 (27.2) — — (27.2) Other comprehensive loss, net of tax — — — — — — (62.6) (62.6) Balance, September 30, 2022 75.3 $ 18.8 $ 230.6 1.3 $ (383.2) $ 2,913.1 $ (308.5) $ 2,470.8 |
Benefit Plans (Tables)
Benefit Plans (Tables) | 9 Months Ended |
Sep. 30, 2023 | |
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract] | |
Schedule of Components of Net Periodic Benefit Cost | The components of net periodic benefit cost for the three months ended September 30 were as follows: Pension benefits Other retirement benefits Total ($ in millions) 2023 2022 2023 2022 2023 2022 Service cost $ 0.2 $ 0.3 $ — $ — $ 0.2 $ 0.3 Interest cost 0.6 0.5 0.1 0.1 0.7 0.6 Expected return on assets (0.4) (0.8) — — (0.4) (0.8) Recognized actuarial losses (gains) 0.2 0.3 (0.5) (0.4) (0.3) (0.1) Settlements — 49.6 — — — 49.6 Net periodic benefit cost $ 0.6 $ 49.9 $ (0.4) $ (0.3) $ 0.2 $ 49.6 Pension benefits Other retirement benefits Total ($ in millions) 2023 2022 2023 2022 2023 2022 U.S. plans $ — $ 49.6 $ (0.4) $ (0.3) $ (0.4) $ 49.3 International plans 0.6 0.3 — — 0.6 0.3 Net periodic benefit cost $ 0.6 $ 49.9 $ (0.4) $ (0.3) $ 0.2 $ 49.6 The components of net periodic benefit cost for the nine months ended September 30 were as follows: Pension benefits Other retirement benefits Total ($ in millions) 2023 2022 2023 2022 2023 2022 Service cost $ 0.8 $ 1.0 $ — $ — $ 0.8 $ 1.0 Interest cost 1.8 3.7 0.2 0.1 2.0 3.8 Expected return on assets (1.0) (5.4) — — (1.0) (5.4) Recognized actuarial losses (gains) 0.5 1.0 (1.6) (1.1) (1.1) (0.1) Settlements — 50.8 — — — 50.8 Net periodic benefit cost $ 2.1 $ 51.1 $ (1.4) $ (1.0) $ 0.7 $ 50.1 Pension benefits Other retirement benefits Total ($ in millions) 2023 2022 2023 2022 2023 2022 U.S. plans $ 0.3 $ 50.3 $ (1.4) $ (1.0) $ (1.1) $ 49.3 International plans 1.8 0.8 — — 1.8 0.8 Net periodic benefit cost $ 2.1 $ 51.1 $ (1.4) $ (1.0) $ 0.7 $ 50.1 |
Other Expense (Income) (Tables)
Other Expense (Income) (Tables) | 9 Months Ended |
Sep. 30, 2023 | |
Other Income and Expenses [Abstract] | |
Schedule of Other Expense (Income) | Other expense (income) consists of: Three Months Ended Nine Months Ended ($ in millions) 2023 2022 2023 2022 Loss on disposal of plant $ — $ — $ 11.6 $ — Asset impairments 3.5 1.4 6.9 1.6 Restructuring and related charges — — (0.8) (1.6) (Gain) loss on oil hedges (0.5) 1.5 0.5 (1.6) Contingent consideration 0.7 1.5 1.5 2.6 Foreign exchange transaction losses (gains) 1.8 (2.2) 3.0 (4.6) Other items 0.1 (0.3) (0.2) (0.4) Total other expense (income) $ 5.6 $ 1.9 $ 22.5 $ (4.0) |
Schedule of Restructuring Reserve | The following table presents activity related to our restructuring obligations related to our 2022 restructuring plan: ($ in millions) Severance Other charges Total Balance, December 31, 2022 $ 10.1 $ 15.3 $ 25.4 (Credits) Charges (0.8) — (0.8) Cash payments (3.7) — (3.7) Non-cash asset write downs — (15.3) (15.3) Balance, September 30, 2023 $ 5.6 $ — $ 5.6 |
Segment Information (Tables)
Segment Information (Tables) | 9 Months Ended |
Sep. 30, 2023 | |
Segment Reporting [Abstract] | |
Schedule of Segment Information | The following table presents information about our reportable segments, reconciled to consolidated totals: Three Months Ended Nine Months Ended ($ in millions) 2023 2022 2023 2022 Net sales: Proprietary Products $ 602.5 $ 567.0 $ 1,803.6 $ 1,822.0 Contract-Manufactured Products 144.9 120.0 414.2 356.5 Intersegment sales elimination — (0.1) — (0.3) Consolidated net sales $ 747.4 $ 686.9 $ 2,217.8 $ 2,178.2 The intersegment sales elimination, which is required for the presentation of consolidated net sales, represents the elimination of components sold between our segments. The following table provides summarized financial information for our segments: Three Months Ended Nine Months Ended ($ in millions) 2023 2022 2023 2022 Operating profit (loss): Proprietary Products $ 181.6 $ 188.6 $ 546.5 $ 615.9 Contract-Manufactured Products 21.0 14.7 53.3 48.0 Total business segment operating profit $ 202.6 $ 203.3 $ 599.8 $ 663.9 Corporate and Unallocated Stock-based compensation expense $ (5.9) $ (6.0) $ (21.9) $ (17.0) Corporate general costs (1) (15.9) (10.9) (47.2) (43.6) Unallocated Items: Loss on disposal of plant (2) — — (11.6) — Cost investment impairment (3) (3.3) — (3.3) — Restructuring and other charges (4) — — (0.1) 1.6 Amortization of acquisition-related intangible assets (5) (0.2) (0.2) (0.6) (0.6) Total Corporate and Unallocated (25.3) (17.1) (84.7) (59.6) Total consolidated operating profit $ 177.3 $ 186.2 $ 515.1 $ 604.3 Interest (income) expense and other nonoperating (income) expense, net (9.7) 50.0 (14.7) 53.1 Income before income taxes and equity in net income of affiliated companies $ 187.0 $ 136.2 $ 529.8 $ 551.2 (1) Corporate general costs includes executive and director compensation, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments. (2) During the nine months ended September 30, 2023, the Company recorded expense of $11.6 million within other expense (income), as a result of the sale of one of the Company’s manufacturing facilities within the Proprietary Products segment. The transaction closed during the second quarter of 2023. (3) During the three and nine months ended September 30, 2023, the Company recorded expense of $3.3 million within other expense (income), as a result of an impairment of one of the Company's cost investments. (4) Restructuring and other charges of $0.1 million for the nine months ended September 30, 2023 represents the net impact of an inventory write down of $0.9 million within cost of goods and services sold and a $0.8 million benefit within other expense (income) for revised severance estimates in connection with its 2022 restructuring plan. During the nine months ended September 30, 2022, the Company recorded a benefit within other expense (income) of $1.6 million for restructuring and severance related costs in connection with its 2020 plan related to revised severance estimates. (5) During the three and nine months ended September 30, 2023, the Company recorded $0.2 million and $0.6 million, respectively, of amortization expense within operating profit associated with an intangible asset acquired during the second quarter of 2020. During the three and nine months ended September 30, 2022, the Company recorded $0.2 million and $0.6 million, respectively, of amortization expense within operating profit associated with an intangible asset acquired during the second quarter of 2020. |
Revenue - Revenue Recognition (
Revenue - Revenue Recognition (Details) - Revenue Benchmark | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Customer Concentration Risk | ||||
Disaggregation of Revenue [Line Items] | ||||
Percentage of net sales | 100% | 100% | 100% | 100% |
Customer Concentration Risk | Biologics | ||||
Disaggregation of Revenue [Line Items] | ||||
Percentage of net sales | 40% | 41% | 37% | 42% |
Customer Concentration Risk | Generics | ||||
Disaggregation of Revenue [Line Items] | ||||
Percentage of net sales | 19% | 18% | 20% | 18% |
Customer Concentration Risk | Pharma | ||||
Disaggregation of Revenue [Line Items] | ||||
Percentage of net sales | 22% | 24% | 24% | 24% |
Customer Concentration Risk | Contract-Manufactured Products | ||||
Disaggregation of Revenue [Line Items] | ||||
Percentage of net sales | 19% | 17% | 19% | 16% |
Product Concentration Risk | ||||
Disaggregation of Revenue [Line Items] | ||||
Percentage of net sales | 100% | 100% | 100% | 100% |
Product Concentration Risk | High-Value Product Components | ||||
Disaggregation of Revenue [Line Items] | ||||
Percentage of net sales | 50% | 54% | 50% | 56% |
Product Concentration Risk | High-Value Product Delivery Devices | ||||
Disaggregation of Revenue [Line Items] | ||||
Percentage of net sales | 11% | 6% | 10% | 5% |
Product Concentration Risk | Standard Packaging | ||||
Disaggregation of Revenue [Line Items] | ||||
Percentage of net sales | 20% | 23% | 21% | 23% |
Product Concentration Risk | Contract-Manufactured Products | ||||
Disaggregation of Revenue [Line Items] | ||||
Percentage of net sales | 19% | 17% | 19% | 16% |
Geographic Concentration Risk | ||||
Disaggregation of Revenue [Line Items] | ||||
Percentage of net sales | 100% | 100% | 100% | 100% |
Geographic Concentration Risk | Americas | ||||
Disaggregation of Revenue [Line Items] | ||||
Percentage of net sales | 46% | 53% | 45% | 48% |
Geographic Concentration Risk | Europe, Middle East, Africa | ||||
Disaggregation of Revenue [Line Items] | ||||
Percentage of net sales | 46% | 38% | 46% | 43% |
Geographic Concentration Risk | Asia Pacific | ||||
Disaggregation of Revenue [Line Items] | ||||
Percentage of net sales | 8% | 9% | 9% | 9% |
Revenue - Contracts and Liabili
Revenue - Contracts and Liabilities (Details) $ in Millions | 9 Months Ended |
Sep. 30, 2023 USD ($) | |
Contract With Customer, Asset [Roll Forward] | |
Contract assets, December 31, 2022 | $ 16.3 |
Contract assets, September 30, 2023 | 19.9 |
Change in contract assets - increase (decrease) | 3.6 |
Contract With Customer, Liability [Roll Forward] | |
Deferred income, December 31, 2022 | (68.2) |
Deferred income, September 30, 2023 | (50) |
Change in deferred income - decrease (increase) | $ 18.2 |
Revenue - Narrative (Details)
Revenue - Narrative (Details) - USD ($) $ in Millions | 9 Months Ended | ||
Sep. 30, 2023 | Dec. 31, 2022 | Jun. 30, 2013 | |
Disaggregation of Revenue [Line Items] | |||
Revenue recognized that was included in the deferred income balance | $ 33.2 | ||
Deferred income | 50 | $ 68.2 | $ 20 |
SmartDose | |||
Disaggregation of Revenue [Line Items] | |||
Deferred income | 2.4 | ||
Deferred income, current | 0.9 | ||
Deferred income, noncurrent | $ 1.5 |
Net Income Per Share - Schedule
Net Income Per Share - Schedule of Net Income Per Share (Details) - USD ($) shares in Millions, $ in Millions | 3 Months Ended | 9 Months Ended | ||||||
Sep. 30, 2023 | Jun. 30, 2023 | Mar. 31, 2023 | Sep. 30, 2022 | Jun. 30, 2022 | Mar. 31, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Earnings Per Share [Abstract] | ||||||||
Net income | $ 161.3 | $ 155.1 | $ 140 | $ 120.6 | $ 188.5 | $ 173.8 | $ 456.4 | $ 482.9 |
Weighted average common shares outstanding (in shares) | 74.3 | 74.4 | 74.4 | 74.4 | ||||
Dilutive effect of equity awards, based on the treasury stock method (in shares) | 1 | 1.3 | 1.1 | 1.5 | ||||
Weighted average shares assuming dilution (in shares) | 75.3 | 75.7 | 75.5 | 75.9 |
Net Income Per Share - Narrativ
Net Income Per Share - Narrative (Details) - USD ($) $ / shares in Units, $ in Millions | 3 Months Ended | 9 Months Ended | ||||||||
Sep. 30, 2023 | Jun. 30, 2023 | Mar. 31, 2023 | Sep. 30, 2022 | Jun. 30, 2022 | Mar. 31, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | Feb. 28, 2023 | Dec. 31, 2021 | |
Earnings Per Share [Abstract] | ||||||||||
Antidilutive options excluded from computation of diluted net income per share (in shares) | 0 | 200,000 | 100,000 | 100,000 | ||||||
Stock repurchase program, shares authorized (in shares) | 1,000,000,000 | 650,000 | ||||||||
Share purchased under share repurchase program (in shares) | 77,329 | 86,667 | 753,399 | 563,334 | ||||||
Stock purchase program, cost of shares purchased | $ 27.8 | $ 173.4 | $ 60.1 | $ 27.2 | $ 28.6 | $ 147.1 | $ 261.3 | $ 202.9 | ||
Stock repurchase program, average price per share (in dollars per share) | $ 360.25 | $ 313.22 | $ 346.86 | $ 360.03 |
Inventories (Details)
Inventories (Details) - USD ($) $ in Millions | Sep. 30, 2023 | Dec. 31, 2022 |
Inventory Disclosure [Abstract] | ||
Raw materials | $ 180.2 | $ 170.7 |
Work in process | 93.8 | 79 |
Finished goods | 157.8 | 165.1 |
Total inventories | $ 431.8 | $ 414.8 |
Leases - Lease Cost (Details)
Leases - Lease Cost (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Leases [Abstract] | ||||
Operating lease cost | $ 4.3 | $ 3.7 | $ 15 | $ 10.4 |
Short-term lease cost | 1.9 | 0.3 | 4.4 | 1.1 |
Variable lease cost | 1.4 | 2.3 | 4.4 | 4.7 |
Total lease cost | $ 7.6 | $ 6.3 | $ 23.8 | $ 16.2 |
Leases - Lease Cash Flow and Su
Leases - Lease Cash Flow and Supplemental Information (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Cash paid for amounts included in the measurement of lease liabilities: | ||||
Operating cash flows from operating leases | $ 4.5 | $ 3.7 | $ 14.4 | $ 10 |
Right-of-use assets obtained in exchange for new operating lease liabilities | $ 3.1 | $ 14 | $ 6.6 | $ 29.5 |
Leases - Lease Weighted Average
Leases - Lease Weighted Average (Details) | Sep. 30, 2023 | Dec. 31, 2022 |
Leases [Abstract] | ||
Weighted average remaining lease term | 10 years 1 month 6 days | 9 years 3 months 18 days |
Weighted average discount rate | 3.46% | 3.25% |
Leases - Maturities of Operatin
Leases - Maturities of Operating Lease Liabilities (Details) - USD ($) $ in Millions | Sep. 30, 2023 | Dec. 31, 2022 |
Leases [Abstract] | ||
Remainder of fiscal year | $ 4.8 | |
Year one | 19.1 | $ 19 |
Year two | 17.1 | 18.1 |
Year three | 14.1 | 16 |
Year four | 9.8 | 13.4 |
Year five | 9.4 | |
Thereafter | 50.6 | |
Thereafter | 50.8 | |
Operating leases liabilities payments due | 115.5 | 126.7 |
Less: imputed lease interest | (16) | (17.7) |
Total lease liabilities | $ 99.5 | $ 109 |
Affiliated Companies (Details)
Affiliated Companies (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | |||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | Dec. 31, 2022 | |
Schedule of Equity Method Investments [Line Items] | |||||
Carrying amount, equity-method investments | $ 189.7 | $ 189.7 | $ 197 | ||
Carrying amount, investments not accounted for under the equity method | 5.7 | 5.7 | 7.9 | ||
Amount due to affiliates | 136.5 | 136.5 | 183.8 | ||
Net sales | 747.4 | $ 686.9 | 2,217.8 | $ 2,178.2 | |
Amount receivable from affiliates | 122.8 | 122.8 | 103 | ||
Affiliated Entity | |||||
Schedule of Equity Method Investments [Line Items] | |||||
Amount due to affiliates | 20.6 | 20.6 | 31.2 | ||
Net sales | 2.5 | 2.6 | 8.5 | 10.2 | |
Amount receivable from affiliates | 1.3 | 1.3 | $ 2.2 | ||
Distributorship Agreement | |||||
Schedule of Equity Method Investments [Line Items] | |||||
Related party transaction, purchases from related party | $ 34.4 | $ 33.6 | $ 118.5 | $ 131.2 |
Debt - Long-term Debt (Details)
Debt - Long-term Debt (Details) - USD ($) $ in Millions | Sep. 30, 2023 | Dec. 31, 2022 |
Debt Instrument [Line Items] | ||
Long-term debt, gross | $ 207.5 | $ 209.2 |
Less: unamortized debt issuance costs | 0.2 | 0.3 |
Total debt | 207.3 | 208.9 |
Less: current portion of long-term debt | 55.2 | 2.2 |
Long-term debt, net | $ 152.1 | 206.7 |
Term Loan, due December 31, 2024 (6.37%) | ||
Debt Instrument [Line Items] | ||
Debt instrument, stated interest rate | 6.37% | |
Long-term debt, gross | $ 81.5 | 83.2 |
Series B notes, due July 5, 2024 (3.82%) | ||
Debt Instrument [Line Items] | ||
Debt instrument, stated interest rate | 3.82% | |
Long-term debt, gross | $ 53 | 53 |
Series C notes, due July 5, 2027 (4.02%) | ||
Debt Instrument [Line Items] | ||
Debt instrument, stated interest rate | 4.02% | |
Long-term debt, gross | $ 73 | $ 73 |
Debt - Narrative (Details)
Debt - Narrative (Details) - USD ($) $ in Millions | Sep. 30, 2023 | Dec. 31, 2022 |
Debt Instrument [Line Items] | ||
Long-term debt, gross | $ 207.5 | $ 209.2 |
Long-term debt | 152.1 | $ 206.7 |
Revolving credit facility, Due 2024 | ||
Debt Instrument [Line Items] | ||
Line of credit facility, current borrowing capacity | 500 | |
Line of credit facility, unused commitment level | 497.6 | |
Revolving credit facility, Due 2024 | Letter of Credit | ||
Debt Instrument [Line Items] | ||
Long-term line of credit | 2.4 | |
Secured Debt | Term Loan, due December 31, 2024 (6.37%) | ||
Debt Instrument [Line Items] | ||
Long-term debt, gross | 81.5 | |
Long-term debt, current | 2.2 | |
Long-term debt | $ 79.3 |
Derivative Financial Instrume_3
Derivative Financial Instruments - Foreign Exchange Rate Risk and Commodity Price Risk (Details) € in Millions, ¥ in Millions, $ in Millions, $ in Millions | 9 Months Ended | 71 Months Ended | |||||
Sep. 30, 2023 SGD ($) $ / bbl bbl | Sep. 30, 2023 SGD ($) $ / bbl bbl | Sep. 30, 2023 EUR (€) $ / bbl | Sep. 30, 2023 USD ($) $ / bbl | Sep. 30, 2023 JPY (¥) $ / bbl | Dec. 31, 2022 SGD ($) | Dec. 31, 2019 USD ($) | |
Foreign Exchange Forward | |||||||
Derivative [Line Items] | |||||||
Derivative contract term | 18 months | ||||||
Options Held | |||||||
Derivative [Line Items] | |||||||
Derivative, nonmonetary notional amount, volume | bbl | 229,397 | 975,206 | |||||
Derivative, average price risk option strike price | $ / bbl | 94.93 | 94.93 | 94.93 | 94.93 | 94.93 | ||
SGD | Currency Forwards | |||||||
Derivative [Line Items] | |||||||
Derivative, notional amount | $ 601.5 | $ 601.5 | $ 13.4 | ||||
SGD | Currency Forwards | Net Investment Hedges: | |||||||
Derivative [Line Items] | |||||||
Derivative, notional amount | 94 | 94 | |||||
SGD | Foreign Exchange Forward | Long | Designated as Hedging Instrument | |||||||
Derivative [Line Items] | |||||||
Derivative, notional amount | $ 44.7 | $ 44.7 | |||||
SGD | Foreign Exchange Forward | Short | Designated as Hedging Instrument | |||||||
Derivative [Line Items] | |||||||
Derivative, notional amount | € 16.8 | $ 15.2 | |||||
USD | Cross Currency Interest Rate Contract | Net Investment Hedges: | |||||||
Derivative [Line Items] | |||||||
Derivative, notional amount | 81.5 | $ 90 | |||||
EUR | Currency Forwards | Net Investment Hedges: | |||||||
Derivative [Line Items] | |||||||
Derivative, notional amount | € | 278.6 | ||||||
EUR | Foreign Exchange Forward | Long | Designated as Hedging Instrument | |||||||
Derivative [Line Items] | |||||||
Derivative, notional amount | € | 20.3 | ||||||
EUR | Foreign Exchange Forward | Short | Designated as Hedging Instrument | |||||||
Derivative [Line Items] | |||||||
Derivative, notional amount | 0 | 22.3 | |||||
Yen | Foreign Exchange Forward | Long | Designated as Hedging Instrument | |||||||
Derivative [Line Items] | |||||||
Derivative, notional amount | ¥ | ¥ 5,159.3 | ||||||
Yen | Foreign Exchange Forward | Short | Designated as Hedging Instrument | |||||||
Derivative [Line Items] | |||||||
Derivative, notional amount | € 9 | $ 29.8 | |||||
Yen | Cross Currency Interest Rate Contract | Net Investment Hedges: | |||||||
Derivative [Line Items] | |||||||
Derivative, notional amount | ¥ | ¥ 8,900 |
Derivative Financial Instrume_4
Derivative Financial Instruments - Effects of Derivative Instruments on OCI and Earnings (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Derivative Instruments, Gain (Loss) [Line Items] | ||||
Total | $ (2) | $ 2.2 | $ (1.7) | $ 4.4 |
Fair Value Hedges: | ||||
Derivative Instruments, Gain (Loss) [Line Items] | ||||
Recognized in earnings, pre-tax, for forward point | 0.2 | 1.1 | 1.6 | 2.8 |
Fair value and net investment hedges, amount of gain (loss) recognized in OCI | (0.3) | (0.4) | (2.3) | 0.3 |
Fair value and net investment hedges, amount of (gain) loss reclassified from accumulated OCI into income | 2.3 | 0.5 | 4.2 | (0.7) |
Cash Flow Hedges: | ||||
Derivative Instruments, Gain (Loss) [Line Items] | ||||
Cash flow hedges, amount of gain (loss) recognized in OCI | (2) | (0.8) | (6.5) | (3.8) |
Cash flow hedges, amount of (gain) loss reclassified from accumulated OCI into income | 1.2 | 0.6 | 2.8 | 1.6 |
Cash Flow Hedges: | Forward treasury locks | ||||
Derivative Instruments, Gain (Loss) [Line Items] | ||||
Cash flow hedges, amount of gain (loss) recognized in OCI | 0 | 0 | 0 | 0 |
Cash flow hedges, amount of (gain) loss reclassified from accumulated OCI into income | 0 | 0.1 | 0.1 | 0.2 |
Net Investment Hedges: | ||||
Derivative Instruments, Gain (Loss) [Line Items] | ||||
Fair value and net investment hedges, amount of gain (loss) recognized in OCI | 2.9 | 4.3 | 10.1 | 13.2 |
Fair value and net investment hedges, amount of (gain) loss reclassified from accumulated OCI into income | 0 | 0 | 0 | 0 |
Other expense (income) | ||||
Derivative Instruments, Gain (Loss) [Line Items] | ||||
Hedged item (intercompany loan) | (1.2) | (14.1) | 8.7 | (35.4) |
Derivative designated as hedging instrument | 0.7 | 14.1 | (10) | 35.4 |
Amount excluded from effectiveness testing | (1.5) | 2.2 | (0.4) | 4.4 |
Other expense (income) | Fair Value Hedges: | Foreign currency hedge contracts | ||||
Derivative Instruments, Gain (Loss) [Line Items] | ||||
Fair value and net investment hedges, amount of gain (loss) recognized in OCI | (0.3) | (0.4) | (2.3) | 0.3 |
Fair value and net investment hedges, amount of (gain) loss reclassified from accumulated OCI into income | 2.3 | 0.5 | 4.2 | (0.7) |
Other expense (income) | Net Investment Hedges: | Cross-currency swap | ||||
Derivative Instruments, Gain (Loss) [Line Items] | ||||
Fair value and net investment hedges, amount of gain (loss) recognized in OCI | 2.9 | 4.3 | 10.1 | 13.2 |
Fair value and net investment hedges, amount of (gain) loss reclassified from accumulated OCI into income | 0 | 0 | 0 | |
Net sales | ||||
Derivative Instruments, Gain (Loss) [Line Items] | ||||
Gain (loss) on derivative instruments, net, pretax | 0.1 | (0.5) | 1.2 | (1.1) |
Net sales | Cash Flow Hedges: | Foreign currency hedge contracts | ||||
Derivative Instruments, Gain (Loss) [Line Items] | ||||
Cash flow hedges, amount of gain (loss) recognized in OCI | 0.5 | 0.7 | (0.4) | 1.1 |
Cash flow hedges, amount of (gain) loss reclassified from accumulated OCI into income | 0.1 | (0.5) | 1.2 | (1.1) |
Cost of goods and services sold | ||||
Derivative Instruments, Gain (Loss) [Line Items] | ||||
Gain (loss) on derivative instruments, net, pretax | 1.1 | 1 | 1.5 | 2.5 |
Cost of goods and services sold | Cash Flow Hedges: | Foreign currency hedge contracts | ||||
Derivative Instruments, Gain (Loss) [Line Items] | ||||
Cash flow hedges, amount of gain (loss) recognized in OCI | (2.5) | (1.5) | (6.1) | (4.9) |
Cash flow hedges, amount of (gain) loss reclassified from accumulated OCI into income | 1.1 | 1 | 1.5 | 2.5 |
Interest expense | ||||
Derivative Instruments, Gain (Loss) [Line Items] | ||||
Gain (loss) on derivative instruments, net, pretax | $ 0 | $ 0.1 | $ 0.1 | $ 0.2 |
Derivative Financial Instrume_5
Derivative Financial Instruments - Derivative Instruments Not Designated as Hedges (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Derivative Instruments, Gain (Loss) [Line Items] | ||||
Gain (loss) on oil hedges | $ 0.5 | $ (1.5) | $ (0.5) | $ 1.6 |
Not Designated as Hedging Instrument | ||||
Derivative Instruments, Gain (Loss) [Line Items] | ||||
Gain (loss) on oil hedges | 0.5 | (1.5) | (0.7) | 1.6 |
Commodity call options | Not Designated as Hedging Instrument | Other expense (income) | ||||
Derivative Instruments, Gain (Loss) [Line Items] | ||||
Gain (loss) on oil hedges | 0.5 | (1.5) | (0.5) | 1.6 |
Currency Forwards | Not Designated as Hedging Instrument | Other expense (income) | ||||
Derivative Instruments, Gain (Loss) [Line Items] | ||||
Gain (loss) on oil hedges | $ 0 | $ 0 | $ (0.2) | $ 0 |
Fair Value Measurements - Asset
Fair Value Measurements - Assets and Liabilities Recorded at Fair Value (Details) - USD ($) $ in Millions | Sep. 30, 2023 | Dec. 31, 2022 |
Assets: | ||
Deferred compensation assets | $ 9.1 | $ 12.5 |
Commodity call options | 1.4 | 1.2 |
Total assets at fair value | 35 | 32.1 |
Liabilities: | ||
Contingent consideration | 4 | 4.7 |
Deferred compensation liabilities | 9.3 | 12.7 |
Total liabilities at fair value | 25.4 | 18.8 |
Foreign currency contracts | ||
Assets: | ||
Foreign currency contracts | 2.4 | 4.5 |
Liabilities: | ||
Foreign currency contracts | 12.1 | 1.4 |
Cross-currency swap | ||
Assets: | ||
Foreign currency contracts | 22.1 | 13.9 |
Level 1 | ||
Assets: | ||
Deferred compensation assets | 9.1 | 12.5 |
Commodity call options | 0 | |
Total assets at fair value | 9.1 | 12.5 |
Liabilities: | ||
Contingent consideration | 0 | 0 |
Deferred compensation liabilities | 9.3 | 12.7 |
Total liabilities at fair value | 9.3 | 12.7 |
Level 1 | Foreign currency contracts | ||
Assets: | ||
Foreign currency contracts | 0 | 0 |
Liabilities: | ||
Foreign currency contracts | 0 | 0 |
Level 1 | Cross-currency swap | ||
Assets: | ||
Foreign currency contracts | 0 | 0 |
Level 2 | ||
Assets: | ||
Deferred compensation assets | 0 | 0 |
Commodity call options | 1.4 | 1.2 |
Total assets at fair value | 25.9 | 19.6 |
Liabilities: | ||
Contingent consideration | 0 | 0 |
Deferred compensation liabilities | 0 | 0 |
Total liabilities at fair value | 12.1 | 1.4 |
Level 2 | Foreign currency contracts | ||
Assets: | ||
Foreign currency contracts | 2.4 | 4.5 |
Liabilities: | ||
Foreign currency contracts | 12.1 | 1.4 |
Level 2 | Cross-currency swap | ||
Assets: | ||
Foreign currency contracts | 22.1 | 13.9 |
Level 3 | ||
Assets: | ||
Deferred compensation assets | 0 | 0 |
Commodity call options | 0 | |
Total assets at fair value | 0 | 0 |
Liabilities: | ||
Contingent consideration | 4 | 4.7 |
Deferred compensation liabilities | 0 | 0 |
Total liabilities at fair value | 4 | 4.7 |
Level 3 | Foreign currency contracts | ||
Assets: | ||
Foreign currency contracts | 0 | 0 |
Liabilities: | ||
Foreign currency contracts | 0 | 0 |
Level 3 | Cross-currency swap | ||
Assets: | ||
Foreign currency contracts | $ 0 | $ 0 |
Fair Value Measurement - Other
Fair Value Measurement - Other Financial Instruments (Details) - USD ($) $ in Millions | Sep. 30, 2023 | Dec. 31, 2022 |
Fair Value Disclosures [Abstract] | ||
Long-term debt, fair value | $ 147.2 | $ 201.8 |
Long-term debt | $ 152.1 | $ 206.7 |
Accumulated Other Comprehensi_3
Accumulated Other Comprehensive Loss - Components of Accumulated Other Comprehensive Income (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | ||||||
Sep. 30, 2023 | Jun. 30, 2023 | Mar. 31, 2023 | Sep. 30, 2022 | Jun. 30, 2022 | Mar. 31, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
AOCI Attributable to Parent, Net of Tax [Roll Forward] | ||||||||
Beginning balance | $ 2,746.7 | $ 2,776.2 | $ 2,684.9 | $ 2,424.4 | $ 2,326.2 | $ 2,335.4 | $ 2,684.9 | $ 2,335.4 |
Other comprehensive (loss) income before reclassifications | (45.9) | (163.3) | ||||||
Amounts reclassified out from accumulated other comprehensive (loss) income | 5.9 | 14.4 | ||||||
Other comprehensive (loss) income, net of tax | (39.5) | (15.1) | 14.6 | (62.6) | (63.5) | (22.8) | (40) | (148.9) |
Ending balance | 2,868.2 | 2,746.7 | 2,776.2 | 2,470.8 | 2,424.4 | 2,326.2 | 2,868.2 | 2,470.8 |
(Losses) gains on derivatives | ||||||||
AOCI Attributable to Parent, Net of Tax [Roll Forward] | ||||||||
Beginning balance | 0.2 | (1.2) | 0.2 | (1.2) | ||||
Other comprehensive (loss) income before reclassifications | (8.8) | (3.5) | ||||||
Amounts reclassified out from accumulated other comprehensive (loss) income | 7 | 0.9 | ||||||
Other comprehensive (loss) income, net of tax | (1.8) | (2.6) | ||||||
Ending balance | (1.6) | (3.8) | (1.6) | (3.8) | ||||
Change in equity affiliate investment AOCI | ||||||||
AOCI Attributable to Parent, Net of Tax [Roll Forward] | ||||||||
Beginning balance | 1.6 | 1.5 | 1.6 | 1.5 | ||||
Other comprehensive (loss) income before reclassifications | (0.1) | (0.2) | ||||||
Amounts reclassified out from accumulated other comprehensive (loss) income | 0 | 0 | ||||||
Other comprehensive (loss) income, net of tax | (0.1) | (0.2) | ||||||
Ending balance | 1.5 | 1.3 | 1.5 | 1.3 | ||||
Defined benefit pension and other postretirement plans | ||||||||
AOCI Attributable to Parent, Net of Tax [Roll Forward] | ||||||||
Beginning balance | (9.4) | (31.8) | (9.4) | (31.8) | ||||
Other comprehensive (loss) income before reclassifications | (0.1) | 2.9 | ||||||
Amounts reclassified out from accumulated other comprehensive (loss) income | (1.1) | 13.5 | ||||||
Other comprehensive (loss) income, net of tax | (1.2) | 16.4 | ||||||
Ending balance | (10.6) | (15.4) | (10.6) | (15.4) | ||||
Foreign currency translation | ||||||||
AOCI Attributable to Parent, Net of Tax [Roll Forward] | ||||||||
Beginning balance | (175.4) | (128.1) | (175.4) | (128.1) | ||||
Other comprehensive (loss) income before reclassifications | (36.9) | (162.5) | ||||||
Amounts reclassified out from accumulated other comprehensive (loss) income | 0 | 0 | ||||||
Other comprehensive (loss) income, net of tax | (36.9) | (162.5) | ||||||
Ending balance | (212.3) | (290.6) | (212.3) | (290.6) | ||||
Accumulated other comprehensive loss | ||||||||
AOCI Attributable to Parent, Net of Tax [Roll Forward] | ||||||||
Beginning balance | (183.5) | (168.4) | (183) | (245.9) | (182.4) | (159.6) | (183) | (159.6) |
Other comprehensive (loss) income, net of tax | (39.5) | (15.1) | 14.6 | (62.6) | (63.5) | (22.8) | ||
Ending balance | $ (223) | $ (183.5) | $ (168.4) | $ (308.5) | $ (245.9) | $ (182.4) | $ (223) | $ (308.5) |
Accumulated Other Comprehensi_4
Accumulated Other Comprehensive Loss - Other Comprehensive Loss Reclassifications (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | ||||||
Sep. 30, 2023 | Jun. 30, 2023 | Mar. 31, 2023 | Sep. 30, 2022 | Jun. 30, 2022 | Mar. 31, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Reclassification out of Accumulated Other Comprehensive Loss [Line Items] | ||||||||
Cost of goods and services sold | $ (459.1) | $ (418.9) | $ (1,366.8) | $ (1,304.1) | ||||
Interest expense | (2.9) | (2.2) | (7.8) | (6.2) | ||||
Actuarial gains | 0.3 | 0.1 | 1.1 | 0.1 | ||||
Settlements | 0 | (49.6) | 0 | (50.8) | ||||
Income before income taxes and equity in net income of affiliated companies | 187 | 136.2 | 529.8 | 551.2 | ||||
Tax (expense) benefit | (29.4) | (20.4) | (87.8) | (85.8) | ||||
Net income | 161.3 | $ 155.1 | $ 140 | 120.6 | $ 188.5 | $ 173.8 | 456.4 | 482.9 |
Reclassification out of Accumulated Other Comprehensive Loss | ||||||||
Reclassification out of Accumulated Other Comprehensive Loss [Line Items] | ||||||||
Net income | (3.3) | (13.4) | (5.9) | (14.4) | ||||
Reclassification out of Accumulated Other Comprehensive Loss | Gains (losses) on derivatives: | ||||||||
Reclassification out of Accumulated Other Comprehensive Loss [Line Items] | ||||||||
Income before income taxes and equity in net income of affiliated companies | (5.1) | (1.5) | (9.9) | (0.9) | ||||
Tax (expense) benefit | 1.6 | 0.4 | 2.9 | 0 | ||||
Net income | (3.5) | (1.1) | (7) | (0.9) | ||||
Reclassification out of Accumulated Other Comprehensive Loss | Gains (losses) on derivatives: | Foreign currency contracts | ||||||||
Reclassification out of Accumulated Other Comprehensive Loss [Line Items] | ||||||||
Net sales | (0.2) | 0.5 | (1.5) | 1.2 | ||||
Cost of goods and services sold | (1.4) | (1.2) | (2) | (2.9) | ||||
Other expense (income) | (3.4) | (0.7) | (6.2) | 1.1 | ||||
Reclassification out of Accumulated Other Comprehensive Loss | Gains (losses) on derivatives: | Forward treasury locks | ||||||||
Reclassification out of Accumulated Other Comprehensive Loss [Line Items] | ||||||||
Interest expense | (0.1) | (0.1) | (0.2) | (0.3) | ||||
Reclassification out of Accumulated Other Comprehensive Loss | Amortization of defined benefit pension and other postretirement plans: | ||||||||
Reclassification out of Accumulated Other Comprehensive Loss [Line Items] | ||||||||
Actuarial gains | 0.3 | 1.1 | 1.1 | 1.1 | ||||
Settlements | 0 | (27.6) | 0 | (28.8) | ||||
Other | 0 | 0 | 0.4 | (0.4) | ||||
Income before income taxes and equity in net income of affiliated companies | 0.3 | (26.5) | 1.5 | (28.1) | ||||
Tax (expense) benefit | (0.1) | 14.2 | (0.4) | 14.6 | ||||
Net income | $ 0.2 | $ (12.3) | $ 1.1 | $ (13.5) |
Shareholder's Equity - Change i
Shareholder's Equity - Change in Shareholders' Equity (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | ||||||
Sep. 30, 2023 | Jun. 30, 2023 | Mar. 31, 2023 | Sep. 30, 2022 | Jun. 30, 2022 | Mar. 31, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||
Beginning balance (in shares) | 75,300,000 | 75,300,000 | ||||||
Beginning balance | $ 2,746.7 | $ 2,776.2 | $ 2,684.9 | $ 2,424.4 | $ 2,326.2 | $ 2,335.4 | $ 2,684.9 | $ 2,335.4 |
Beginning balance (in shares) | 1,200,000 | 1,200,000 | ||||||
Net income | 161.3 | 155.1 | $ 140 | 120.6 | 188.5 | 173.8 | $ 456.4 | $ 482.9 |
Activity related to stock-based compensation | $ 27.5 | 18 | 11 | $ 15.6 | 15.1 | 0.1 | ||
Share purchased under share repurchase program (in shares) | 77,329 | 86,667 | 753,399 | 563,334 | ||||
Shares purchased under share repurchase program | $ (27.8) | (173.4) | (60.1) | $ (27.2) | (28.6) | (147.1) | $ (261.3) | $ (202.9) |
Dividends declared | (14.1) | (14.2) | (13.3) | (13.2) | ||||
Other comprehensive income (loss), net of tax | $ (39.5) | (15.1) | 14.6 | (62.6) | (63.5) | (22.8) | $ (40) | (148.9) |
Ending balance (in shares) | 75,300,000 | 75,300,000 | ||||||
Ending balance | $ 2,868.2 | $ 2,746.7 | $ 2,776.2 | $ 2,470.8 | $ 2,424.4 | $ 2,326.2 | $ 2,868.2 | $ 2,470.8 |
Ending balance (in shares) | 1,300,000 | 1,300,000 | ||||||
Common Stock | ||||||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||
Beginning balance (in shares) | 75,300,000 | 75,300,000 | 75,300,000 | 75,300,000 | 75,300,000 | 75,300,000 | 75,300,000 | 75,300,000 |
Beginning balance | $ 18.8 | $ 18.8 | $ 18.8 | $ 18.8 | $ 18.8 | $ 18.8 | $ 18.8 | $ 18.8 |
Ending balance (in shares) | 75,300,000 | 75,300,000 | 75,300,000 | 75,300,000 | 75,300,000 | 75,300,000 | 75,300,000 | 75,300,000 |
Ending balance | $ 18.8 | $ 18.8 | $ 18.8 | $ 18.8 | $ 18.8 | $ 18.8 | $ 18.8 | $ 18.8 |
Capital in Excess of Par Value | ||||||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||
Beginning balance | 158.2 | 181.4 | 232.2 | 225.3 | 219.9 | 249 | 232.2 | 249 |
Activity related to stock-based compensation | (35.6) | (23.2) | (50.8) | 5.3 | 5.4 | (29.1) | ||
Ending balance | 122.6 | 158.2 | 181.4 | 230.6 | 225.3 | 219.9 | 122.6 | 230.6 |
Treasury Stock | ||||||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||
Beginning balance | $ (501.4) | $ (369.2) | $ (370.9) | $ (366.3) | $ (347.4) | $ (229.5) | $ (370.9) | $ (229.5) |
Beginning balance (in shares) | 1,400,000 | 1,100,000 | 1,200,000 | 1,300,000 | 1,200,000 | 1,100,000 | 1,200,000 | 1,100,000 |
Activity related to stock-based compensation | $ 63.1 | $ 41.2 | $ 61.8 | $ 10.3 | $ 9.7 | $ 29.2 | ||
Activity related to stock -based compensation (in shares) | (200,000) | (200,000) | (300,000) | (100,000) | (300,000) | |||
Share purchased under share repurchase program (in shares) | 100,000 | 500,000 | 200,000 | 100,000 | 100,000 | 400,000 | ||
Shares purchased under share repurchase program | $ (27.8) | $ (173.4) | $ (60.1) | $ (27.2) | $ (28.6) | $ (147.1) | ||
Ending balance | $ (466.1) | $ (501.4) | $ (369.2) | $ (383.2) | $ (366.3) | $ (347.4) | $ (466.1) | $ (383.2) |
Ending balance (in shares) | 1,300,000 | 1,400,000 | 1,100,000 | 1,300,000 | 1,300,000 | 1,200,000 | 1,300,000 | 1,300,000 |
Retained earnings | ||||||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||
Beginning balance | $ 3,254.6 | $ 3,113.6 | $ 2,987.8 | $ 2,792.5 | $ 2,617.3 | $ 2,456.7 | $ 2,987.8 | $ 2,456.7 |
Net income | 161.3 | 155.1 | 140 | 120.6 | 188.5 | 173.8 | ||
Dividends declared | (14.1) | (14.2) | (13.3) | (13.2) | ||||
Ending balance | 3,415.9 | 3,254.6 | 3,113.6 | 2,913.1 | 2,792.5 | 2,617.3 | 3,415.9 | 2,913.1 |
Accumulated other comprehensive loss | ||||||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||
Beginning balance | (183.5) | (168.4) | (183) | (245.9) | (182.4) | (159.6) | (183) | (159.6) |
Other comprehensive income (loss), net of tax | (39.5) | (15.1) | 14.6 | (62.6) | (63.5) | (22.8) | ||
Ending balance | $ (223) | $ (183.5) | $ (168.4) | $ (308.5) | $ (245.9) | $ (182.4) | $ (223) | $ (308.5) |
Shareholder's Equity - Suppleme
Shareholder's Equity - Supplemental Equity Information (Details) - $ / shares | 3 Months Ended | |||
Jun. 30, 2023 | Mar. 31, 2023 | Jun. 30, 2022 | Mar. 31, 2022 | |
Equity [Abstract] | ||||
Dividends declared per share (in dollars per share) | $ 0.19 | $ 0.19 | $ 0.18 | $ 0.18 |
Stock-Based Compensation (Detai
Stock-Based Compensation (Details) - USD ($) $ / shares in Units, $ in Millions | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Shares available for issuance under the 2016 Plan (in shares) | 1,438,454 | 1,438,454 | ||
Stock options, granted (in shares) | 105,640 | |||
Stock options, weighted average exercise price (in dollars per share) | $ 306.92 | |||
Stock options, weighted average grant date fair value (in dollars per share) | $ 108.88 | |||
Risk-free interest rate (in hundredths) | 4.10% | |||
Expected life (in years) | 5 years 8 months 12 days | |||
Stock volatility (in hundredths) | 29.80% | |||
Dividend yield (in hundredths) | 0.30% | |||
Stock-based compensation expense | $ 5.9 | $ 6 | $ 21.9 | $ 17 |
Performance Share Unit (PSUs) | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Granted (in shares) | 37,536 | |||
Grant date fair value (in dollars per share) | $ 306.91 | |||
Performance Share Unit (PSUs) | Minimum | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Target award percentage | 0% | |||
Performance Share Unit (PSUs) | Maximum | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Target award percentage | 200% | |||
Restricted Stock Units (RSUs) | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Granted (in shares) | 4,563 | |||
Grant date fair value (in dollars per share) | $ 310.56 |
Benefit Plans - Schedule of Com
Benefit Plans - Schedule of Components of Net Periodic Benefit Cost (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items] | ||||
Service cost | $ 0.2 | $ 0.3 | $ 0.8 | $ 1 |
Interest cost | 0.7 | 0.6 | 2 | 3.8 |
Expected return on assets | (0.4) | (0.8) | (1) | (5.4) |
Recognized actuarial losses (gains) | (0.3) | (0.1) | (1.1) | (0.1) |
Settlements | 0 | 49.6 | 0 | 50.8 |
Net periodic benefit cost | 0.2 | 49.6 | 0.7 | 50.1 |
U.S. plans | ||||
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items] | ||||
Net periodic benefit cost | (0.4) | 49.3 | (1.1) | 49.3 |
International plans | ||||
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items] | ||||
Net periodic benefit cost | 0.6 | 0.3 | 1.8 | 0.8 |
Pension benefits | ||||
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items] | ||||
Service cost | 0.2 | 0.3 | 0.8 | 1 |
Interest cost | 0.6 | 0.5 | 1.8 | 3.7 |
Expected return on assets | (0.4) | (0.8) | (1) | (5.4) |
Recognized actuarial losses (gains) | 0.2 | 0.3 | 0.5 | 1 |
Settlements | 0 | 49.6 | 0 | 50.8 |
Net periodic benefit cost | 0.6 | 49.9 | 2.1 | 51.1 |
Pension benefits | U.S. plans | ||||
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items] | ||||
Net periodic benefit cost | 0 | 49.6 | 0.3 | 50.3 |
Pension benefits | International plans | ||||
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items] | ||||
Net periodic benefit cost | 0.6 | 0.3 | 1.8 | 0.8 |
Other retirement benefits | ||||
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items] | ||||
Service cost | 0 | 0 | 0 | 0 |
Interest cost | 0.1 | 0.1 | 0.2 | 0.1 |
Expected return on assets | 0 | 0 | 0 | 0 |
Recognized actuarial losses (gains) | (0.5) | (0.4) | (1.6) | (1.1) |
Settlements | 0 | 0 | 0 | 0 |
Net periodic benefit cost | (0.4) | (0.3) | (1.4) | (1) |
Other retirement benefits | U.S. plans | ||||
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items] | ||||
Net periodic benefit cost | (0.4) | (0.3) | (1.4) | (1) |
Other retirement benefits | International plans | ||||
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items] | ||||
Net periodic benefit cost | $ 0 | $ 0 | $ 0 | $ 0 |
Benefit Plans - Narrative (Deta
Benefit Plans - Narrative (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items] | ||||
Settlements | $ 0 | $ 49.6 | $ 0 | $ 50.8 |
Pension benefits | ||||
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items] | ||||
Settlements | $ 0 | $ 49.6 | 0 | $ 50.8 |
U.S. plans | ||||
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items] | ||||
Contributions by employer | $ 6.5 |
Other Expense (Income) - Summar
Other Expense (Income) - Summary (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Other Income and Expenses [Abstract] | ||||
Loss on disposal of plant | $ 0 | $ 0 | $ 11.6 | $ 0 |
Asset impairments | 3.5 | 1.4 | 6.9 | 1.6 |
Restructuring and related charges | 0 | 0 | (0.8) | (1.6) |
(Gain) loss on oil hedges | (0.5) | 1.5 | 0.5 | (1.6) |
Contingent consideration | 0.7 | 1.5 | 1.5 | 2.6 |
Foreign exchange transaction losses (gains) | 1.8 | (2.2) | 3 | (4.6) |
Other items | 0.1 | (0.3) | (0.2) | (0.4) |
Total other expense (income) | $ 5.6 | $ 1.9 | $ 22.5 | $ (4) |
Other Expense (Income) - Narrat
Other Expense (Income) - Narrative (Details) $ in Millions | 1 Months Ended | 3 Months Ended | 9 Months Ended | ||
Dec. 31, 2022 USD ($) | Sep. 30, 2023 USD ($) | Sep. 30, 2022 USD ($) | Sep. 30, 2023 USD ($) facility | Sep. 30, 2022 USD ($) | |
Restructuring Cost and Reserve [Line Items] | |||||
Loss on disposal of plant | $ 0 | $ 0 | $ 11.6 | $ 0 | |
Number of loss on disposal manufacturing facility | facility | 1 | ||||
Restructuring and related activities, period of implementation | 24 months | ||||
Gain (loss) on oil hedges | $ 0.5 | $ (1.5) | $ (0.5) | $ 1.6 | |
Minimum | |||||
Restructuring Cost and Reserve [Line Items] | |||||
Restructuring and related cost, expected cost | $ 25 | ||||
Effect on future earnings, amount | 22 | ||||
Maximum | |||||
Restructuring Cost and Reserve [Line Items] | |||||
Restructuring and related cost, expected cost | 27 | ||||
Effect on future earnings, amount | $ 24 |
Other Expense (Income) - Restru
Other Expense (Income) - Restructuring and Related Charges (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Restructuring Reserve [Roll Forward] | ||||
(Credits) Charges | $ 0 | $ 0 | $ (0.8) | $ (1.6) |
2022 Restructuring Plan | ||||
Restructuring Reserve [Roll Forward] | ||||
Balance, December 31, 2022 | 25.4 | |||
(Credits) Charges | (0.8) | |||
Cash payments | (3.7) | |||
Non-cash asset write downs | (15.3) | |||
Balance, September 30, 2023 | 5.6 | 5.6 | ||
Severance and benefits | 2022 Restructuring Plan | ||||
Restructuring Reserve [Roll Forward] | ||||
Balance, December 31, 2022 | 10.1 | |||
(Credits) Charges | (0.8) | |||
Cash payments | (3.7) | |||
Non-cash asset write downs | 0 | |||
Balance, September 30, 2023 | 5.6 | 5.6 | ||
Other charges | 2022 Restructuring Plan | ||||
Restructuring Reserve [Roll Forward] | ||||
Balance, December 31, 2022 | 15.3 | |||
(Credits) Charges | 0 | |||
Cash payments | 0 | |||
Non-cash asset write downs | (15.3) | |||
Balance, September 30, 2023 | $ 0 | $ 0 |
Income Taxes (Details)
Income Taxes (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Income Tax Disclosure [Abstract] | ||||
Provision for income taxes | $ 29.4 | $ 20.4 | $ 87.8 | $ 85.8 |
Effective income tax rate | 15.70% | 15% | 16.60% | 15.60% |
Tax benefit from termination of pension plans | $ 20 | $ 20.3 | ||
Effective income tax rate reconciliation tax benefit | $ 5.9 |
Segment Information (Details)
Segment Information (Details) $ in Millions | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2023 USD ($) | Sep. 30, 2022 USD ($) | Sep. 30, 2023 USD ($) facility segment | Sep. 30, 2022 USD ($) | |
Segment Reporting [Abstract] | ||||
Number of reportable segments | segment | 2 | |||
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] | ||||
Net sales | $ 747.4 | $ 686.9 | $ 2,217.8 | $ 2,178.2 |
Operating profit | 177.3 | 186.2 | 515.1 | 604.3 |
Stock-based compensation expense | (21.9) | (17) | ||
Loss on disposal of plant | 0 | 0 | (11.6) | 0 |
Interest (income) expense and other nonoperating (income) expense, net | (9.7) | 50 | (14.7) | 53.1 |
Income before income taxes and equity in net income of affiliated companies | 187 | 136.2 | $ 529.8 | 551.2 |
Number of loss on disposal manufacturing facility | facility | 1 | |||
Operating Segments | ||||
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] | ||||
Operating profit | 202.6 | 203.3 | $ 599.8 | 663.9 |
Intersegment sales elimination | ||||
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] | ||||
Net sales | 0 | (0.1) | 0 | (0.3) |
Corporate and Unallocated | ||||
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] | ||||
Operating profit | (25.3) | (17.1) | (84.7) | (59.6) |
Stock-based compensation expense | (5.9) | (6) | (21.9) | (17) |
Corporate general costs | (15.9) | (10.9) | (47.2) | (43.6) |
Loss on disposal of plant | 0 | 0 | (11.6) | 0 |
Cost investment impairment | (3.3) | 0 | (3.3) | 0 |
Amortization of acquisition-related intangible assets | (0.2) | (0.2) | (0.6) | (0.6) |
Corporate and Unallocated | 2022 Restructuring Plan | ||||
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] | ||||
Restructuring and other charges | 0 | 0 | (0.1) | 1.6 |
Inventory write-down | 0.9 | |||
Corporate and Unallocated | 2022 Restructuring Plan | Other Operating Income (Expense) | ||||
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] | ||||
Benefit within other expense (income) for revised severance estimates | 0.8 | |||
Proprietary Products | Operating Segments | ||||
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] | ||||
Net sales | 602.5 | 567 | 1,803.6 | 1,822 |
Operating profit | 181.6 | 188.6 | 546.5 | 615.9 |
Contract-Manufactured Products | Operating Segments | ||||
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] | ||||
Net sales | 144.9 | 120 | 414.2 | 356.5 |
Operating profit | $ 21 | $ 14.7 | $ 53.3 | $ 48 |